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Summary 
Although coronary artery disease (CAD) is a leading cause of both angina pectoris and 
Heart Failure (HF), little is known of the relationship between these two conditions.  
This is the focus of my thesis (1, 2).  
Chapter one gives an overview of these two clinical conditions and presents the 
findings of a literature review examining the prognostic importance of angina in HF.   
Subsequent chapters present the results of a series of retrospective analyses, using data 
collected from large randomized controlled trials.  
In the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) 4878 
patients with Heart Failure and Reduced Ejection Fraction (HF-REF) were divided 
into three groups according to their history of angina.  Patients with past and current 
angina were compared with a reference group of patients with no angina.  Current 
angina was strongly associated with greater functional limitation despite an absence of 
clinical features of worsening HF.  Current angina was also associated with a higher 
risk of acute coronary syndrome (ACS) but all cause mortality was similar to patients 
with no angina.  Patients with past angina were also at higher risk of ACS but the 
association was not as strong as in patients with current angina(3, 4).   
In CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and 
Morbidity) I sought to validate the findings of CORONA whilst also investigating the 
importance of angina in patients with Heart Failure and Preserved Ejection Fraction 
(HF-PEF).  CHARM enrolled 7599 patients with HF into three discrete trials 
according to left ventricular ejection fraction (LVEF) and angiotensin converting 
enzyme inhibitor (ACEI) use: CHARM-Preserved (LVEF>40%), CHARM-Added 
(LVEF ≤40% receiving ACE inhibitor treatment) and CHARM-Alternative (LVEF 
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≤40% not receiving an ACE inhibitor due to intolerance).  As in CORONA, in 
CHARM patients with current angina and HF-REF were more likely to experience 
greater function limitation and were at higher risk of ACS than patients with no 
angina.  In CHARM I was also able to demonstrate a similar trend in patients with HF-
PEF and current angina(3, 5, 6). 
Investigators in the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-
Preserve) study did not distinguish between past and current angina.  Therefore this 
analysis examined the prognostic importance of a history of CAD and angina in 4128 
patients with HF-PEF.  The most important finding from this study was the higher risk 
of sudden death and all-cause mortality in patients with HF-PEF and a history of 
CAD.  This association was present irrespective of whether or not patients had a 
history of angina pectoris(7, 8). 
In the Prospective comparison of Angiotensin Receptor–Neprilysin Inhibitor with 
ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure 
(PARADIGM-HF) 8442 patients with CAD and HF-REF were categorized into four 
groups according to severity of angina.  There was a stepwise increase in functional 
limitation with worsening severity of angina.  When compared with patients with no 
angina, patients with severe angina were also at significantly higher risk of fatal and 
non-fatal outcomes including all-cause death (9). 
These analyses highlight the importance of angina symptoms on functional class and 
prognosis in patients with HF.  Identification of high-risk groups could guide future 
treatment strategies.  More specifically there may be the potential for coronary 
revascularization or pharmacotherapy to improve outcomes in these subgroups but 
such strategies need to be tested in prospective randomised controlled trials. 
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Introduction 
	   18	  
CAD is a leading cause of both angina and HF but despite this common association, 
the relationship between these two conditions is incompletely understood(1, 2, 10-13).  
This is the focus of my thesis.   
1.1 Angina Pectoris 
1.1.1 Definition of Angina Pectoris 
The European Society of Cardiology (ESC) guidelines on the management of stable 
coronary artery disease define typical angina as ‘substernal chest discomfort of 
characteristic quality and duration, provoked by exertion or emotional stress and 
relieved by rest and/or nitrates within minutes’(13).  Many patients present with 
atypical angina where only some of these features are present or breathlessness on 
exertion otherwise referred to as angina equivalent(14-18).         
Angina occurs as a consequence of myocardial ischaemia, usually due to 
atherosclerosis that results in narrowing of the coronary arteries impairing the supply 
of blood and oxygen to the myocardium.  Atherosclerosis can begin in childhood and 
progresses at a variable rate depending on a patient’s genetic predisposition and risk 
factors.  These risk factors include diabetes mellitus, smoking, hypertension and 
elevated cholesterol (15, 19, 20).   
As well as atherosclerosis, numerous factors affecting the demand or supply of oxygen 
to the myocardium can contribute to angina symptoms.  These include microvascular 
obstruction, left ventricular hypertrophy and anaemia(21-23).   
Severity of angina symptoms are graded using the Canadian Cardiovascular Society 
(CCS) scale:  
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Class 1: Only occurs with strenuous exertion.  Everyday activities do not precipitate 
angina. 
Class 2: Mild limitation of ordinary everyday activity.  Angina brought on by walking 
uphill, emotion, cold weather or meals. 
Class 3: Significant limitation of ordinary physical activity (e.g. a single flight of stairs 
at a normal pace). 
Class 4: Inability to carry out basic tasks without bringing on angina.  In some cases, 
angina may even be present at rest(24). 
1.1.2 Epidemiology of Angina Pectoris 
Epidemiological studies of angina are challenging due to the way in which angina is 
coded in community databases.  In Scotland, general practitioners reported rates of 
angina of 23.3 per 1000 population in males and 34.3 per 1000 in females aged 65–74.  
After the age of 75 this increased to 38.5 and 59.7 per 1000 respectively.  From 2008 
to 2010, a Scottish Health Survey Topic Report on Older People’s Health found the 
overall prevalence of angina was 15% in females and 18% in males over the age of 
65(25). 
1.1.3 Investigation and Diagnosis of Angina Pectoris 
The differential diagnosis of chest discomfort is wide and includes pulmonary, 
gastrointestinal and musculoskeletal conditions.  Clinicians may make a diagnosis of 
angina from history alone but without objective evidence of ischaemia or obstructive 
coronary artery disease, patients will often be misdiagnosed.  The National Institute 
for Health and Care Excellence (NICE) recommend confirmatory diagnostic testing in 
all patients describing typical or atypical angina(26, 27).     
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The diagnostic yield from the electrocardiogram (ECG) is low and is most likely to be 
abnormal during an acute angina attack.  At rest, it may reveal evidence of prior 
myocardial infarction or risk factors such as hypertension and should be performed in 
all patients with suspected angina(15).   
Functional tests looking for myocardial ischaemia are often the first line investigation.  
Exercise tolerance testing (ETT) is a well-established investigation with a number of 
benefits.  It is widely available, has a good safety profile and offers reasonable 
sensitivity, particularly in patients with multi-vessel disease.  The main drawback of 
ETT is its poor specificity and it performs less well in obese patients, females and 
those with baseline abnormalities on ECG(28-31).  A number of alternative functional 
tests with improved diagnostic accuracy are now available, e.g. myocardial perfusion 
imaging, stress echocardiography and cardiac magnetic resonance imaging.  Each 
modality has particular strengths and weaknesses but all generally have less 
availability and additional expense relative to ETT(15, 28, 30, 32-34). 
Multidetector computed tomography (CT) coronary angiography and invasive 
coronary angiography are anatomical investigations that assess for stenosis of the 
epicardial coronary arteries.  Both NICE and SIGN guidelines recommend CT 
coronary angiography as the first line diagnostic test.  Whilst it has excellent negative 
predictive value the main drawback is the risk of over diagnosing obstructive CAD, 
particularly in high-risk patients with calcified arteries(32, 35, 36).  Invasive coronary 
angiography remains the gold standard test and is mandatory in all patients being 
considered for coronary revascularisation.  Recent advances in coronary angiography 
including intravascular ultrasonography and guidewires with pressure or flow sensors 
have further enhanced its diagnostic utility(15, 37, 38).  
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1.1.4 Management of Angina Pectoris 
Treatment goals in stable angina are to reduce symptoms and improve prognosis.   
Pharmacological therapy 
Anti-anginal agents are the mainstay of medical therapy.  Whilst there is no 
convincing evidence any anti-anginal therapy improves prognosis, beta-blockers or 
rate limiting calcium channel blockers are commonly prescribed in the first instance.  
A variety of second line agents are available, including oral nitrate preparations, 
nicorandil and ivabradine(39, 40).   
The benefits of antiplatelet therapy in stable angina were confirmed in the Swedish 
Angina Pectoris Aspirin Trial (SAPAT).  This double-blinded, randomised controlled 
trial compared Aspirin to placebo in 2035 patients.  Patients prescribed Aspirin had a 
reduced risk of the primary endpoint of myocardial infarction and sudden death(41).  
Clopidogrel may be used as an alternative to Aspirin.  In a randomised controlled trial 
of 19185 patients with stable atherosclerotic disease (22% with stable angina), 
Clopidogrel was associated with a reduced risk of the composite endpoint of 
ischaemic stroke, myocardial infarction and vascular death when compared with 
Aspirin(25, 42). 
Patients with stable angina should receive lipid-lowering therapy.   In a large meta-
analysis of over 90000 patients, including patients with chronic stable angina, statin 
use was associated with significant reductions in all-cause death and cardiovascular 
(CV) endpoints(25, 43).   
Whilst statins remains the mainstay of lipid lowering therapy, a number of other 
agents have been shown to improve cardiovascular outcomes in recent years.  
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Ezetimibe is an agent that reduces LDL cholesterol by preventing cholesterol 
absorption.  In IMPROVE-IT, the combination of ezetimibe and simvastatin was 
associated with a reduction in the composite endpoint of CV death, non-fatal MI, 
unstable angina, coronary revascularization or nonfatal stroke, when compared with 
simvastatin monotherapy(44).   
Randomised controlled trials have also demonstrated the efficacy of PCSK9 inhibitors, 
novel agents that act by preventing destruction of cholesterol receptors in the liver, 
thereby facilitating the removing of LDL cholesterol from the bloodstream.  The 
ODYSSEY OUTCOMES trial was a large randomized controlled trial that compared 
alirocumab with placebo in patients on maximally tolerated doses of statins post ACS.  
Alirocumab use was associated with a significant reduction in the primary composite 
end point of death from CAD, nonfatal MI, fatal or nonfatal ischemic stroke, or 
unstable angina requiring hospitalization(45).  
Studies examining the use of ACE inhibitors in patients with stable angina have 
produced conflicting results.  However, a large meta-analysis concluded ACE 
inhibitors were associated with significant reductions in all-cause mortality, informing 
the SIGN guideline recommendation that ACE inhibitors be considered in all patients 
with stable angina(25, 46-50). 
Coronary revascularisation 
COURAGE was a randomised controlled trial of 2287 patients with coronary disease 
and objective evidence of myocardial ischaemia comparing percutaneous coronary 
intervention (PCI) with optimal medical therapy.  Patients with HF were excluded.  As 
an initial management strategy PCI did not reduce the risk of death, myocardial 
infarction, or other major cardiovascular events(51).  Coronary revascularisation with 
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PCI or coronary artery bypass graft surgery (CABG) is indicated in patients with on-
going angina despite optimal medical therapy.  In a minority of patients with 
‘prognostically significant’ CAD, revascularisation may be indicated despite adequate 
symptom control.  Whilst there is a lack of consensus over the definition of 
prognostically significant CAD, the ESC guidelines include patients with significant 
left main stem or proximal left anterior descending artery disease, multi-vessel disease 
and patients with large areas of ischaemia on non-invasive testing(15).  The role of 
revascularisation in patients with HF or LVSD is discussed further in section 1.2.4 
below.   
1.1 Heart Failure 
1.2.1 Definition of Heart Failure 
The ESC guidelines define heart failure as a ‘clinical syndrome characterized by 
typical symptoms (e.g. breathlessness, ankle swelling and fatigue) that may be 
accompanied by signs (e.g. elevated jugular venous pressure, pulmonary crackles and 
peripheral oedema) caused by a structural and/or functional cardiac abnormality, 
resulting in a reduced cardiac output and/or elevated intracardiac pressures at rest or 
during stress’(13).   
Historically, HF has been divided into two subtypes depending on the left ventricular 
ejection fraction (LVEF), a specific measure of the hearts function.  Heart Failure with 
reduced ejection fraction (HF-REF) is usually defined as a LVEF <40% whereas Heart 
Failure with preserved ejection fraction (HF-PEF) has historically been defined as a 
LVEF >40 or 45%.  Since the design and analyses contained in this thesis, a third 
intermediate category, Heart Failure with mid range ejection fraction (HFmrEF) has 
been introduced, aiming to identify the optimal treatment strategy in patients with 
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modest reductions in their LVEF(13, 52). This subgroup is not examined further in 
this thesis.   
The New York Heart Association (NYHA) classification describes the severity of HF 
according to patient’s functional limitations and symptoms: 
NYHA class 1: No symptoms during everyday physical activity. 
NYHA class 2: Mild limitation of everyday physical activity.   
NYHA class 3: Significant limitations with symptoms of HF brought on by less than 
ordinary everyday activity.  
NYHA class 4: Symptoms of HF are present at rest with worsening on exertion(13). 
1.2.2 Epidemiology of Heart Failure 
HF has been referred to as ‘a rising global epidemic’ that is estimated to affect almost 
40 million people worldwide.  Frequency increases with age and in patients over 80, 
around 10% have a diagnosis of HF(12, 53).	  	        
There is no consensus over how best to establish HF aetiology and this has not been 
evaluated in a systematic fashion.  Patients with HF can have multiple potential 
aetiologies that are not mutually exclusive.  The Framingham heart study cited 
hypertension as the commonest cause of HF, either as a primary or contributory cause.  
However, Framingham used only clinical criteria to diagnose HF and did not 
differentiate HF-REF vs. HF-PEF.  Subsequent studies have not supported such a 
central role for hypertension in the development of HF-REF.  Moreover, although 
hypertension is a strong risk factor for development of CAD, the importance of 
hypertension as a sole cause of LV systolic dysfunction in Western countries remains 
unclear.  More contemporary randomized controlled trials and observational studies 
frequently identify CAD as the leading cause of HF-REF in the developed world (1, 
11, 54, 55).  HF epidemiology data in developing nations has not been robustly 
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collected but infectious causes and nutritional deficiencies are considered important 
factors.  However, as developing countries undergo transition periods with 
increasingly aged populations disease burden is shifting to more chronic diseases as 
seen in western populations.  As a result CAD has also emerged as a more significant 
cause of HF in the developing world (26).   
Epidemiology studies in HF-PEF are complicated by a lack of consensus over the 
conditions definition and how it is best diagnosed(56).  Allowing for these important 
limitations it is estimated HF-PEF accounts for 44-72% of all HF cases.  Recognised 
risk factors include ageing, hypertension, diabetes and female sex.  CAD is common 
in patients with HF-PEF but its precise role remains incompletely understood.  Whilst 
it may be central to the development of HF-PEF in some patients, in others it may 
simply coexist without a direct mechanistic relationship(57, 58). 
1.2.3 Investigation and Diagnosis of Heart Failure 
Clinical features of HF are non-specific and clinicians should have a low threshold for 
initiating investigation.      
The 12 lead ECG and natriuretic peptide biomarkers are often used as screening tests 
in patients with clinical features suggestive of HF.  Although specificity is poor, a 
normal ECG makes a HF diagnosis unlikely(59).  Similarly, in the acute setting, 
normal B-type natriuretic peptide (BNP) or N-terminal pro b-type natriuretic peptide 
(NT-proBNP) essentially exclude HF but diagnostic accuracy falls in patients with 
stable symptoms.  Natriuretic peptides also provide important prognostic information 
in patients with confirmed diagnoses(60, 61).    
Definitive diagnosis requires objective cardiac dysfunction or structural abnormality. 
This is usually defined by imaging, the cornerstone of which is echocardiography.  
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This is a widely available test, which provides detailed information including data on 
systolic and diastolic function, chamber size, valvular heart disease and pulmonary 
artery pressures(62, 63).  In patients where echocardiography is non-diagnostic other 
tools such as Cardiac MRI may need to be considered(64, 65).         
1.2.4 Management of patients with Heart Failure 
Pharmacological therapy 
Diuretic therapy is used to treat fluid overload and relieve symptoms in HF(66).   
Patients with HF-REF should be treated with neuro-hormonal antagonists, which have 
been shown to improve clinical outcomes in this population.  These include beta-
blockers, ACE inhibitors, angiotensin receptor blockers and mineralocorticoid 
receptor antagonists (MRA)(67-71).  More recently, Sacubitril Valsartan (formerly 
LCZ696), a first-in-class angiotensin receptor neprilysin inhibitor (ARNI) was 
approved for use having demonstrated superiority over ACE inhibitors in the 
PARADIGM-HF trial.  Chapter six of this thesis presents the findings of a 
retrospective analysis of PARADIGM-HF(9).    
Patients with HF-REF, with resting heart rates of more than 70 beats per minute (on 
beta blockers if tolerated), may also benefit from Ivabradine.  This selective sinus 
node inhibitor reduced the risk of HF death and worsening HF in the SHIFT trial(72).     
A number of studies have evaluated pharmacotherapy in HF-PEF but to date no 
medication has been shown to improve prognosis in these patients(13).    
Device therapy  
Patients with HF have a higher risk of arrhythmia and sudden cardiac death.  
Implantable cardioverter defibrillators (ICD) reduce this risk by correcting bradycardia 
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and treating ventricular arrhythmias(73, 74).  Current guidelines recommend 
implantation in patients with HF-REF, NYHA class II-III symptoms and LVEF <35% 
following optimal medical therapy(13).  
Cardiac resynchronisation therapy (CRT) has also been shown to improve morbidity 
and mortality in appropriately selected patients(75).  CRT is currently recommended 
in symptomatic patients with HF-REF, prolonged QRS durations and LVEF ≤35% 
despite optimal medical therapy(13).   
Few studies have evaluated the role of device therapy in HF-PEF and at present 
neither ICD or CRT is recommended in this group of patients(13, 76).    
Coronary revascularisation 
The role of coronary revascularisation in patients with HF and obstructive CAD is 
controversial.  In the Surgical Treatment for Ischemic Heart Failure (STICH) study, a 
large randomised controlled trial examining the use of CABG in patients with severe 
LV systolic dysfunction, patients randomised to CABG were at lower risk of all-cause 
mortality during long-term follow-up(77).  The role of PCI in this population is 
currently being evaluated in the Study of Efficacy and Safety of Percutaneous 
Coronary Intervention to Improve Survival in Heart Failure (REVIVED-BCIS2) 
trial(78).   
A common hypothesis focuses on the concept of ‘hibernating’ and ‘viable’ 
myocardium.  This proposes that a subset of patients exposed to significant myocardial 
ischaemia demonstrate reduced contractility that normalises (or improves) when 
coronary blood flow is restored.  This would have the potential to identify patients 
most likely to benefit from coronary revascularisation.  However, questions remain 
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over how best to identify and define patients with viability and the concept has yet to 
be proven in the setting of prospective, randomised controlled trials(79, 80).  In the 
aforementioned STICH trial, viability was not shown to be predictive of improved 
clinical outcomes(77, 81).     
1.3 Angina Pectoris in Heart Failure 
Given the overlapping aetiologies of HF and angina, it is not surprising angina occurs 
commonly in this population.  The reported prevalence of angina varies widely, 
ranging from 7-39% in patients with non-differentiated diagnosis of heart failure and 
13-59% and 4-46% in patients with HF-REF and HF-PEF respectively(71, 82-99).  
The reasons for the large differences in reported prevalence are multifactorial.  Whilst 
differences in the populations being studied are likely a significant factor, perhaps 
more importantly, there is a lack of standardisation and few studies report how angina 
was diagnosed.  In many studies, the diagnosis was based on investigator-determined 
responses on clinical response forms, without mandating objective supporting 
evidence from non-invasive imaging tests or coronary angiography.   
As detailed in section 1.1.1, obstructive CAD is the commonest cause of angina.  
However, several studies have demonstrated evidence of myocardial ischaemia or 
angina in patients with normal coronary arteries on angiography.  Myocardial 
ischaemia in idiopathic dilated cardiomyopathy was assessed in one study of 22 
patients with HF-REF and angiographically normal coronary arteries.  Compared with 
a control group, patients with idiopathic dilated cardiomyopathy had significantly 
more ischaemia on positron emission tomography.  The extent of myocardial 
ischaemia correlated with increased wall stress, which increased oxygen demand and 
impaired coronary flow reserve (decreasing oxygen supply).  This demand supply 
mismatch was exacerbated during exercise, resulting in worsening ischaemia(100).  In 
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another single-centre study of 376 consecutive patients with HF-PEF referred for 
coronary angiography, the percentage of patients reporting angina was similar in those 
with and without obstructive CAD on angiography(58).  These findings support the 
concept that other mechanisms such as microvascular obstruction and left ventricular 
hypertrophy play an important role in demand and supply of oxygen to the 
myocardium in HF.  
In the following subsection the findings from a literature review of angina in HF are 
presented.  
Angina in HF literature review 
Search strategy   
Medline, EMBASE and Cochrane electronic databases were searched from 1990 to 
June 2014. The MESH term, ‘Angina pectoris’ and the keyword angina were used to 
define angina pectoris.  Heart failure and left ventricular dysfunction were defined 
using the MESH terms, ‘Ventricular Dysfunction, Left’ and ‘Heart Failure’ and 
keywords including: congestive heart failure, left ventricular systolic dysfunction, 
systolic heart failure, and cardiac failure. Only English language publications were 
considered and case reports, letters, editorials and studies with fewer than 250 
participants were excluded.  The cut-off of 250 patients was agreed by consensus.  
Similarly, reports in paediatric populations, hypertrophic cardiomyopathy and 
congenital heart disease were omitted. References of studies selected for inclusion 
were hand searched, as were risk prediction models from major trials referenced in the 
European Society of Cardiology and American College of Cardiology HF guidelines. 
Study selection 
Two authors (Athar Badar and Alan Brunton) independently screened articles by title 
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and abstract using a hierarchal approach and the full texts of all potentially relevant 
studies were examined.  All studies examining the relationship between angina and 
clinical outcomes in patients with HF were eligible for inclusion, provided an adjusted 
analysis was performed.  However, the focus of the review was on the association of 
angina with functional status, mortality, ACS and HF events.  Both reviewers 
independently extracted and recorded data detailing study type, data source, number of 
patients per study, patient characteristics and outcomes.  Data were compared to 
ensure accuracy.  Adjusted outcomes were presented as they appeared in the original 
studies.   
Results  
Searches from MEDLINE, EMBASE and the Cochrane Library generated 3706, 
10094, and 740 results respectively.  An additional 205 potential studies were 
identified from hand searches of reference lists and other sources.  After removal of 
duplicates, 14171 articles were screened.  443 full-text studies were reviewed and after 
assessment for eligibility, only 7 studies were included in the final analysis (see figure 
1).  An overview of the studies characteristics is presented in table 1 and the findings 
are discussed below(85, 98, 99, 101-104).     
Clinical Characteristics and Prognosis of patients with Angina in Heart Failure 
Relationship between angina and functional class 
Only two studies reported the relationship between angina and functional status in HF.  
Both single centre, retrospective studies were from the Duke Databank for 
Cardiovascular Disease.  In 2376 patients with HF-REF referred for angiography, 
those describing recent angina (defined as within the last six weeks) were compared to 
patients with no recent angina.  In this highly selected group, patients with recent 
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angina were less likely to describe NYHA class III or IV symptoms than patients with 
no angina (21% vs. 27%; p<0.001)(85).  The second study examined 3517 with HF-
PEF.  This also found patients with recent angina were significantly less likely to have 
a high functional class when compared with patients with no angina (60% vs. 75%).  
However, in this study, patients with angina had a number of clinical features 
suggesting better HF status, namely lower mean resting heart rate, higher mean blood 
pressure and a reduced frequency of crepitations and third heart sounds on 
examination(98).   
Relationship between angina and all-cause mortality in patients with HF 
The three studies to report on the relationship between angina and all-cause mortality 
in HF are presented in table 2(85, 98, 99).   
HF-REF 
Retrospective analyses from the Carvedilol Or Metoprolol European Trial (COMET) 
(n=3029; 53% with ischemic aetiologies) and the Duke Databank for Cardiovascular 
Disease demonstrated no significant association between the presence of angina and 
higher all-cause mortality(85, 99).  
HF-PEF 
In the unadjusted analysis from the Duke Databank for Cardiovascular Disease 
(n=3517) patients with angina were at lower risk of all-cause mortality when 
compared with patients with no angina.  However, after adjusting for other significant 
variables, this association was no longer statistically significant(98). 
Relationship between angina and acute coronary events in patients with HF 
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Coronary events were included as part of composite endpoints in several studies but 
only one study examined the association between angina and an individual coronary 
endpoint.  In a retrospective analysis from the Digitalis Investigation Group (DIG), 
investigators examined the predictors of unstable angina (UA) hospitalizations in 7716 
patients with HF (6800 with HF-REF and 916 with HF-PEF). A risk prediction model 
identified current angina as a significant predictor of hospitalizations for UA (adjusted 
HR 2.08 (1.82-2.37); p<0.0001)(103). 
Relationship between angina and HF outcomes in patients with HF  
In COMET there was no significant association between angina and HF endpoints in 
patients with HF-REF(99).  
Relationship between angina and other clinical outcomes in patients with HF  
The relationship between angina and a range of other outcomes in patients with HF are 
detailed in table 3(85, 98, 101, 102, 104).  
Limitations 
The data presented above has a number of significant limitations.   
All the studies identified in this review were retrospective analyses and these therefore 
share the inherent limitations of such analyses.   
The number of studies assessing the relationship between angina and clinical 
outcomes in HF was very small.  Only seven studies were identified in total with only 
three examining the relationship between angina and all-cause death and only single 
studies assessing the relationship between angina and HF or coronary outcomes.     
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The two studies from the Duke Databank for Cardiovascular disease defined angina as 
‘chest pain within the past six weeks’ but investigators included patients with both 
typical and atypical chest pain.  It is not clear how many of these patients truly had 
angina(85, 98).  Please see appendix 1 for assessment of bias in these two studies.   
In other studies stable angina was not the focus of the analysis and data was limited to 
a tabulated hazard ratio assessing the importance of angina on clinical outcomes.  In 
these studies details of how angina was defined or diagnosed was not available.  
Similarly, although the retrospective analysis of the DIG study reported the prognostic 
importance of current angina, other studies did not distinguish between patients with 
past or current symptoms(103).   
The quality of multivariate analyses varied significantly across different studies.  
Greenburg et al did not list the variables used in the multivariate analysis whereas 
others studies failed to identify for important covariates such as history of 
revascularisation(102).   
Using large datasets from randomised controlled trials, this thesis sets out to examine 
the prognostic importance of angina in patients with HF.  It aims to assess the 
significance of active symptoms (i.e. current angina) and the severity of angina in 
patients with HF.  Identifying patients at higher risk of adverse outcomes may enable 
us to test specific treatment strategies in this group with the goal of improving patient 
outcomes.   
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Figure 1: Literature search: Study Selection 
  
14540	  records	  identified	  through	  
database	  searches:	  
(Medline	  3706,	  Embase	  10094,	  
Cochrane	  Library	  740)	  
	  
205	  additional	  records	  identified	  
through	  other	  sources	  
14171	  records	  screened	  after	  duplicates	  
removed	  
13728	  records	  excluded	  after	  
screening	  of	  title	  and	  abstract	  
	  
443	  full-­‐text	  articles	  
reviewed	  
436	  articles	  excluded	  due	  to:	  
Lack	  of	  usable	  data	  (n=434)	  
Small	  sample	  size	  (n=2)	  
7	  studies	  included	  in	  
qualitative	  synthesis	  
	   35	  
Table 1 Study Characteristics: results of literature search. 
Author 
(Year) 
Study/ 
design 
Sample size HF population Adjustment 
Ahmed(103) 
(2007) 
DIG 
Retrospective 
7788  
(HF-REF 
6800;  
HF-PEF 
988) 
HF-REF and HF-
PEF (analysed as 
single group) 
69% ischaemic 
aetiology 
 
Activity, age, BMI, BP, 
cardiomegaly, creatinine, 
diabetes, dyspnoea, heart 
rate, HF aetiology, HF 
duration, hypertension, 
increased JVP, lower limb 
oedema, medications, 
NYHA class, potassium, 
previous MI, pulmonary 
congestion, rales, race, sex, 
3rd heart sound and 6 or 
more symptoms or signs 
Ekman(99) 
(2005) 
COMET 
Retrospective 
3029 HF-REF  
53% ischaemic 
aetiology 
Age, antiarrhythmic, ECG 
findings, Carvedilol use, 
diabetes, digitalis, FH, 
HgB, HF duration, lipid-
lowering drugs, LVEF, 
nitrates, NYHA class, prior 
MI, creatinine, sodium, sex, 
stroke, BP and weight 
(mortality analysis) 
Greenberg 
(102) (2006) 
COHERE 
registry 
Retrospective 
4280 Unselected 
community HF 
population  
56% with CAD 
Final list of variables 
included in multivariable 
model not presented in 
manuscript 
Lam(101)  
(2012) 
I-PRESERVE 
Retrospective 
4128 HF-PEF  
25% ischaemic 
aetiology 
AF, age, COPD/asthma, 
CVD, diabetes, eGFR, heart 
rate, HgB, HF cause, recent 
HF hospitalization, 
hypertension, log NT-
proBNP, LVEF, 
medications, MI, neutrophil 
count, NYHA class, 
obesity, PCI/CABG, 
smoking, systolic, BP and 
valve disease 
Mentz(85)  
(2012)  
Duke databank 
Retrospective 
single-centre 
2376 HF-REF 
100% with a 
history of CAD 
Age, baseline medications, 
BMI, CVD, diabetes, heart 
rate, hypertension, LVEF, 
number of diseased vessels, 
NYHA class, previous 
CABG, previous PCI, PVD, 
race, serum 
creatinine/sodium/urea 
nitrogen/hemoglobin, sex 
and smoking history 
Mentz(98)  
(2014)  
Duke databank 
Retrospective 
single-centre 
3517 HF-PEF 
consecutive 
referrals to large 
single-centre  
100% with a 
Age, baseline medications, 
BMI, Charlson Index, 
CVD, diabetes, heart rate, 
hyperlipidaemia, 
hypertension, LVEF, 
NYHA class, previous 
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history of CAD coronary revascularization, 
previous smoking history, 
prior MI, PVD, serum 
creatinine/HgB/sodium/ 
urea, sex, systolic BP, race, 
ventricular gallop 
Richter  
(2009)(104) 
Alberta registry 
Retrospective 
448 Acute HF 
presentations 
39% with a 
history of CAD 
AF, age, asthma, baseline 
medications, CAD, COPD, 
diabetes, dyslipidaemia, 
history of HF, hypertension, 
previous MI, renal disease, 
revascularization, sex, 
smoking status, stroke 
     
ApoA -­‐ apolipoprotein A1, ApoB - apolipoprotein B, AF -­‐ atrial fibrillation, BBB -­‐ bundle branch 
block, BMI -­‐ body mass index, BP -­‐	  blood pressure, CABG -­‐ coronary artery bypass graft surgery, 
CAD -­‐ coronary artery disease, CHARM - Candesartan in Heart failure Assessment of Reduction 
in Mortality and morbidity, COHERE - the coreg heart failure registry, COMET - Carvedilol Or 
Metoprolol European Trial, COPD -­‐ chronic obstructive pulmonary disease, CORONA - 
Controlled Rosuvastatin Multinational Trial in Heart failure, CVD -­‐ cerebrovascular disease, DIG -­‐ 
Digitalis Investigation Group, ECG -­‐	  electrocardiogram, eGFR -­‐ estimated glomerular filtration 
rate, FH -­‐ family history, HF -­‐ heart failure, HF-PEF -­‐ heart failure with preserved ejection 
fraction, HF-REF -­‐ heart failure with reduced ejection fraction, HFH -­‐ heart failure hospitalization, 
HgB -­‐ haemaglobin, hs-CRP -­‐ high sensitivity C-reactive protein, ICD -­‐ implantable 
cardiodefibrillator, I-PRESERVE - Irbesartan in Heart Failure with Preserved Ejection Fraction 
Study, JVP -­‐ jugular venous pressure, log NT-proBNP - N-terminal pro-brain natriuretic peptide, 
LVEF -­‐ left ventricular ejection fraction, MI -­‐ myocardial infarction, NYHA -­‐ New York Heart 
Association, PCI -­‐ percutaneous coronary intervention, PVD -­‐	  peripheral vascular disease, TSH -­‐ 
thyroid stimulating hormone 
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Table 2 Studies reporting the relationship between angina and all-cause death in 
heart failure 
Author  
(Year) 
Comparison 
Unadjusted 
analysis* 
Adjusted analysis* 
Ekman(99)  
(2005)  
Current angina (vs. no current 
angina) 
Unadjusted outcomes presented 
as relative risk ratios 
1.09 (1.00–1.20); 0.05 ns (HR not reported)  
 
Mentz(85)  
(2012)  
HF-REF 
Angina within the last 6 weeks 
vs. no angina in the last 6 
weeks 
Outcomes presented as 5 year 
event rates 
43 vs. 41%; 0.07 41 vs. 41%; 0.32 
 
Mentz(98)  
(2014)  
HF-PEF 
Angina within the last 6 weeks 
vs. no angina in the last 6 
weeks 
Unadjusted outcomes presented 
as 5 year event rates 
36.2 vs. 30.1; 0.002 0.94 (0.82-1.06); 0.30 
 
*All outcomes presented as HRs unless otherwise stated. 
Parenthesis in the comparison column contain the presumed reference group when not 
explicitly stated in main manuscript 
HF-PEF – heart failure with preserved ejection fraction, HF-REF – heart failure with reduced 
ejection fraction, ns – non-significant. 
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Table 3 Studies reporting the relationship between angina and other outcomes in 
heart failure. 
 
Author  
(Year) 
Comparison Outcome 
Unadjusted 
analysis* 
Adjusted 
analysis* 
Ekman(99) 
(2005)  
Current angina (vs. 
no current angina) 
*Unadjusted 
outcomes presented 
as relative risk 
ratios 
All-Cause 
Hospitalization  
 
1.23 (1.15–
1.31); 
<0.0001 
 
ns (HR not 
reported)  
Greenberg 
(102)(2006)  
History of angina  
(vs. no history of 
angina) 
*Adjusted 
outcomes presented 
as odds ratios 
Death, 
hospitalization 
for HF, or 
hospitalization 
for CV reasons 
other than HF 
- 1.315 
(1.117–
1.549); 
0.0010  
Lam(101) 
(2012)  
History of angina 
(vs. no history of 
angina) 
All-cause events 
(male) 
- 1.117 
(0.947–
1.317); 0.191 
All-cause events 
(female) 
- 1.020 
(0.880–
1.182); 0.795 
Mentz(85) 
(2012)  
(HF-REF) 
Angina within the 
last 6 weeks vs. no 
angina in the last 6 
weeks  
*Outcomes 
presented as 5 year 
event rates 
Death or MI 48 vs. 46%;  
0.10 
47 vs. 46%;  
0.15 
Death, MI or 
revascularization 
83 vs. 85%;  
0.31 
87 vs 85%;  
0.01 
Death or 
Hospitalization 
85 vs. 87%;  
0.29 
85 vs. 87%;  
0.37 
CV death or CV 
hospitalization 
72 vs. 77%;  
0.01 
73 vs. 77%;  
0.03 
Mentz(98) 
(2014)  
(HF-PEF) 
Angina within the 
last 6 weeks vs. no 
angina in the last 6 
Death or MI 37.7 vs. 32.9;  
0.019 
0.93 (0.82-
1.06);  
0.27  
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weeks 
*Unadjusted 
outcomes presented 
as 5 year event 
rates 
Death, MI or 
revascularization 
44.5 vs. 57.1;  
<0.001 
1.29 (1.15-
1.43); 
<0.0001 
Death, MI or 
stroke 
40.9 vs. 38.4;  
0.33 
0.99 (0.87-
1.11);  
0.81 
Death, MI, 
revascularization 
or stroke 
47.0 vs. 52.9;  
<0.001 
1.30 (1.17-
1.45); 
<0.0001 
CV death or CV 
hospitalization  
63.7 vs. 61.1;  
0.12 
0. 95 (0.85-
1.05);  
0.32 
Richter 
(2009)(104)  
Angina (vs. no 
angina)  
*Adjusted 
outcomes presented 
as odds ratios   
Readmission or 
death at 30 days 
following acute 
HF admission 
- 0.46 (0.21–
0.97) 
*All outcomes presented as HRs unless otherwise stated. 
Parenthesis in the comparison column contain presumed reference group when not explicitly 
stated in main manuscript 
HF – heart failure, CV – cardiovascular, HF-PEF – heart failure with preserved ejection fraction, 
HF-REF – heart failure with reduced ejection fraction, MI – myocardial infarction, ns – non-
significant. 
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My thesis examines the clinical importance of angina in patients with heart failure.  
More specifically I use a series of retrospective analyses to evaluate the importance of 
both the presence and severity of angina symptoms on patient outcomes.  My 
hypothesis was that the presence and severity angina pectoris would be associated 
with more adverse clinical outcomes in patients with heart failure.  The hypotheses 
from the individual analyses are detailed in the relevant chapters. 
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Chapter 2  
Methodology 
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My thesis investigated the clinical importance of angina pectoris in patients with HF.  
After completion of the literature search as described above, the main body of the 
thesis was based on a series of retrospective analyses, using data collected from large 
randomised controlled trials.  Trial funders from the individual studies (namely 
CORONA, CHARM, I-Preserve and PARADIGM-HF) gave the databases to the 
academic leaders of the trials interested in pursuing further analyses relevant to better 
understanding of the disease and its treatment.  All analyses were performed using 
Cox proportional hazards regression analysis. All statistical analyses performed in 
preparation of this thesis used the STATA software package (version 13, Stata Corp, 
College Station, Texas, the United States of America).  Further details of the 
methodology of the individual analyses are detailed below.    
 
CORONA 
The CORONA trial enrolled 5011 patients who were at least 60 years of age with 
NYHA class II–IV heart failure, a left ventricular ejection fraction ≤40% (≤35% if 
NYHA class II) and an ischaemic aetiology (as defined by investigators). Only 
patients deemed clinically stable, on optimal medical therapy and without an 
investigator-determined indication for cholesterol-lowering therapy were eligible for 
inclusion. Exclusion criteria included a history of statin-induced myopathy or 
hypersensitivity reaction; recent acute coronary syndrome or stroke; coronary 
revascularization, CRT or ICD implantation within the last three months; cardiac 
transplantation; pericardial disease; acute myocarditis; hypertrophic cardiomyopathy; 
significant systemic disease (e.g. amyloidosis); significant (primary) uncorrected 
valvular heart disease; significant renal or hepatic impairment; or any other condition 
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expected to markedly impact upon life expectancy or reduce compliance with the 
study protocol(3, 4, 106).    
Ethics committees from participating institutes approved the trial and all patients gave 
written consent. Randomized patients received either once daily rosuvastatin at a dose 
of 10mg or placebo. After a median follow-up period of 32.8 months there was no 
significant reduction in the risk of the primary composite endpoint of CV death, non-
fatal MI, or non-fatal stroke in patients receiving rosuvastatin(3, 4, 106). 
Investigators documented a history of ‘past or current angina’ by ticking boxes on the 
case report form.  A history of ‘chest pain over the past few days’ was also recorded at 
the time of enrolment. For the purpose of this analysis patients were divided into three 
groups: group A (those without a history of angina or chest pain at baseline i.e. no 
angina), group B (those with a history of angina but no chest pain at baseline i.e. past 
angina) and group C (those with a history of angina and chest pain at baseline i.e. 
current angina). Patients without a documented history of ‘past or current angina’ who 
still reported chest pain at baseline were not considered in the analysis (n = 133)(3). 
Clinical outcomes 
The endpoints analysed in this retrospective analysis included all-cause mortality, the 
composite of CV death or HF hospitalization, CV death, HF hospitalization and three 
coronary endpoints.  In CORONA the pre-specified secondary ‘coronary event’ 
endpoint was defined as a composite of sudden death, fatal or non-fatal MI, 
hospitalization for UA, PCI or CABG, ventricular defibrillation by ICD or 
resuscitation after cardiac arrest.  The more restricted composite of non-fatal MI, UA, 
PCI, or CABG was also examined in order to exclude events such as resuscitation 
after cardiac arrest or sudden death, which do not always occur as a consequence of 
	   44	  
myocardial ischaemia or infarction.  Finally, I examined the composite endpoint of 
non-fatal MI or UA to allow for the fact coronary revascularization may be a 
reflection of physician preference as much as disease activity(3). 
Statistical analysis 
Baseline characteristics for the three groups were presented using percentages for 
categorical variables and means with standard deviations for continuous variables 
(medians were used when data were not normally distributed). The chi-squared test 
was used to compare categorical variables and the one-way analysis of variance test 
was used for continuous variables(3). 
Outcomes were compared in patients with group B versus group A (i.e. past versus no 
angina) and group C versus group A (i.e. current versus no angina) using Cox 
proportional-hazard models regression analyses. Univariate and multivariate analyses 
were performed. Previously published predictors of prognosis in CORONA were used 
in the multivariate analysis; the prognostically significant variables in that model 
were: age, gender, LVEF, NYHA functional class, heart rate, systolic blood pressure, 
BMI, coronary revascularization, MI, smoking, stroke, baseline atrial 
fibrillation/flutter, intermittent claudication, aortic aneurysm, diabetes, hypertension, 
pacemaker and ICD implantations, (log) NT-proBNP, creatinine, alanine 
aminotransferase, thyroid stimulating hormone, creatine kinase, C-reactive protein, 
ApoA-1 and ApoB(107). Adjustment was also made for differences in baseline 
medications (specifically diuretic use, beta-blockers, ACE inhibitors or ARBs, 
aldosterone antagonists, digoxin, anti-arrhythmic agents, antiplatelet or anticoagulant 
medication and randomization to rosuvastatin). The Schoenfeld residuals method was 
used to assess proportional hazard assumptions. Fatal outcomes (and composite 
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endpoints containing fatal and non-fatal components) were presented using Kaplan–
Meier curves; non-fatal outcomes were analyzed using the cumulative incidence 
function, taking into account the competing risk of all-cause death. A p-value of <0.05 
was regarded statistically significant(3). 
 
CHARM 
The CHARM program enrolled 7599 patients with NYHA class II-IV HF symptoms 
into one of three parallel trials according to ACE inhibitor use and LVEF at the time 
of trial entry: CHARM-Preserved (LVEF>40%, n=3023), CHARM-Added (LVEF 
≤40% receiving ACE inhibitor treatment, n=2548) and CHARM-Alternative (LVEF 
≤40% not receiving an ACE inhibitor due to prior intolerance, n=2028).  All patients 
received standard medical therapy and were randomized to candesartan, titrated up to 
a maximally tolerated dose of up to 32mg once daily or matching placebo.  Ethics 
committees from each participating institute approved the trial and patients provided 
informed written consent.  The median follow-up was 38 months(5, 6, 114, 115).   
Our analysis focused on the patients in CHARM with a history of ischaemic heart 
disease; this was defined as a primary or contributing cause of HF, prior coronary 
revascularization or a history of MI as recorded on the case report form (CRF) 
(n=5408).  A history of ‘past’ or ‘present’ angina was also recorded on the CRF and 
patients were divided into three groups; patients with no history of angina (group A), 
those with a prior history of angina but no active symptoms (group B) and those with 
current angina (group C). Outcomes were compared in patients with past and current 
angina with the reference group of patients with no angina as detailed below.  Patients 
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with HF-REF and HF-PEF were analysed separately (the latter was defined as a LVEF 
>45%)(5). 
Clinical Outcomes  
Endpoints examined in this analysis were as follows: all-cause death (the primary 
endpoint of the overall CHARM program), CV death or HF hospitalization, CV death, 
HF hospitalization, fatal or nonfatal MI, MI or UA and the composite of MI, UA or 
coronary revascularization(5).   
Statistical analysis 
The baseline characteristics for groups were presented using percentages for 
categorical variables and means with standard deviations for continuous variables. The 
chi-square test was used to compare categorical variables and the ANOVA to compare 
continuous variables.  The relationship between past or current angina and the 
endpoints detailed above were examined using Cox proportional-hazard models.  Both 
univariate and multivariate analyses were performed.  The multivariate analysis used a 
previously published risk prediction model from the CHARM program.  All-cause 
death was adjusted for age, sex, body mass index, NYHA class, LVEF, BBB on ECG, 
previous HF hospitalization, diabetes mellitus, cardiomegaly and smoking history; HF 
and coronary endpoints were adjusted for age, NYHA class, heart rate, BBB on ECG, 
LVEF, diastolic blood pressure, duration of heart failure, previous HF hospitalization, 
diabetes mellitus and cardiomegaly(116).  Kaplan-Meier curves were presented by 
symptom category.  All analyses considered a two-tailed p value < 0.05 as statistically 
significance(5).  
 
I-PRESERVE 
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The I-PRESERVE trial enrolled 4128 patients aged ≥60 years of age with a LVEF of 
≥45%, a recent HF hospitalisation or NYHA class II-IV symptoms and findings 
consistent with HF-PEF on echocardiography or ECG.  To fulfil ECG criteria patients 
had to have evidence of specific features indicating moderate or severe LVH [e.g. SV1 
RV5 or RV6 O3.5 mV (35 mm at normal standard), RaVL O1.1 mV (11 mm at 
normal standard)].  Patients were randomized to receive irbesartan at a dose of 300mg 
once daily or matching placebo.  After a mean follow-up of 49.5 months, no 
significant difference was observed in the risk of death from any cause or 
hospitalization for a CV cause (the primary composite outcome) or in the pre-specified 
secondary endpoints(7, 8, 121, 122).  
Heart failure aetiology and past medical history including prior MI, coronary 
revascularization and stable angina pectoris were recorded in the CRF.  For the 
purposes of the analysis a history of coronary artery disease was defined as a history 
of previous MI, PCI, CABG or a primary ischemic aetiology as defined by 
investigators.  Patients were divided into four groups; patients with no history of CAD 
or angina (group A), those without a history of CAD who were documented as having 
a history of angina (group B), patients with a history of CAD who had no history of 
angina (group C) and those with a history of both CAD and angina (group D)(7).  	  
Clinical outcomes 
Outcomes were compared in patients from group B versus group A, group C versus 
group A and group D versus group A.  The outcomes assessed were HF death or HF 
hospitalization (the HF composite endpoint from I-PRESERVE), HF hospitalization, 
fatal or non-fatal MI, MI or UA, all-cause death, CV death, pump failure death and 
sudden death(7).  
Statistical analysis 
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Baseline characteristics were presented with means and standard deviations for 
continuous variables and percentages for categorical variables.  The ANOVA test was 
used to compare continuous variables and the chi-square test to compare categorical 
variables(7).	  
The relationship between CAD, angina and the above endpoints was examined using 
Cox proportional-hazard models analyses.  Previously published predictors of 
outcomes in I-PRESERVE study were used in the multivariate analysis.  The variables 
adjusted were age, heart rate, ejection fraction, recent HF hospitalization, NT-proBNP; 
log levels, chronic obstructive pulmonary disease or asthma, diabetes mellitus, 
glomerular filtration rate, neutrophil count (log) and disease-specific quality of life 
measured using the Minnesota living with HF questionnaire; additionally left bundle 
branch block was included in the sudden death analysis(7, 123, 124).  Kaplan-Meier 
curves were presented by groups.  A two-tailed p value < 0.05 as the statistical level of 
significance.  
 
PARADIGM-HF 
In PARADIGM-HF a total of 8442 patients with NYHA class II-IV symptoms, an 
ejection fraction of ≤40% and an elevated plasma B-type natriuretic peptide or NT-
proBNP level, were randomized to 200mg twice daily of sacubitril/valsartan or 10 mg 
twice daily of enalapril. Ethics committees from each participating institute approved 
the trial and all patients provided informed consent. The primary endpoint was a 
composite of death from CV causes or HF hospitalization, but the trial was powered to 
identify a difference in the rates of death from CV causes. After a median follow-up 
period of 27 months, the trial was stopped early, according to pre-specified guidelines 
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of over-whelming benefit(9, 128, 129).  
Investigators recorded details of past medical history and heart failure aetiology at 
baseline. For the purposes of the present analysis, a history of CAD was defined as an 
angiographically proven stenosis of ≥50% in at least one major coronary artery, a 
history of myocardial infarction (MI), prior coronary revascularization, investigator-
reported ischaemic aetiology or a history of CAD as defined by investigators. Patients 
with a history of CAD were further categorized into four mutually exclusive groups 
according to the severity of angina symptoms at baseline, as defined by the CCS score: 
no angina, mild (CCS class I symptoms), moderate (class II symptoms) and severe 
angina (class III or IV symptoms).    
Clinical outcomes 
Patients with mild, moderate and severe angina were compared to the reference group 
of patients with CAD but no angina for the following clinical outcomes: the composite 
of CV death or HF hospitalization (the primary endpoint of PARADIGM-HF) and it 
components, hospitalization for unstable angina (UA), hospitalization for non-fatal MI 
and two composite coronary endpoints, UA or non-fatal MI and fatal or non-fatal MI.  
I also investigated the relationship between angina severity and all-cause death, as 
well as and the two major modes of CV death (i.e. sudden death and death due to 
HF)(9).  
Statistical analysis 
Baseline characteristics for each group were presented using means and standard 
deviations for continuous variables (or medians if data were not normally distributed) 
and percentages for categorical variables. The Chi-square test was used to compare 
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categorical variables and the one-way analysis of variance (ANOVA) test was used to 
compare continuous variables.  
The relationships between severity of angina symptoms and outcomes were assessed 
using Cox proportional-hazard regression analyses and Kaplan-Meier survival curves. 
Known predictors of outcome in patients with HF (from the Meta-analysis Global 
Group in Chronic Heart Failure (MAGGIC) prognostic model) were used in the 
multivariable analyses, namely age, ejection fraction, NYHA class, serum creatinine, 
diabetes mellitus, chronic obstructive airway disease, beta blocker use, systolic blood 
pressure, body mass index, time from first diagnosis of HF, smoking status and 
gender(130).  Adjustments were also made for (log) NT-proBNP and randomization to 
LCZ696. Proportional hazards assumptions were checked using the Schoenfeld 
residual method. Both the multivariable models and the survival analysis used a two-
tailed p value < 0.05 as the statistical level of significance. Finally, an interaction 
analysis was also performed to examine the effect of LCZ696 versus enalapril 
according to angina status.  
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Chapter 3 
The relationship between angina pectoris and outcomes in 
patients with heart failure and reduced ejection fraction: a 
retrospective analysis of the Controlled Rosuvastatin 
Multinational Trial in Heart Failure (CORONA). 
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3.1 Introduction 
As described above, although CAD is the leading cause of HF-REF in the developed 
world, little is known about the importance of symptomatic myocardial ischaemia (i.e. 
angina) in this population(11). Whilst a limited number of studies have described past 
history of angina at baseline few have reported whether patients had current angina at 
the time of enrollment. Similarly, most studies examining the relationship between 
CAD and prognosis in HF have focused on aetiology without distinguishing between 
patients with and without angina(3, 11, 105).  
Angina symptoms may reflect viable myocardium susceptible to infarction, placing 
patients with reduced LVEF at risk of further adverse outcomes. The presence of 
myocardial ischaemia without infarction might also have important prognostic 
implications. Accordingly, in this retrospective analysis I examined the clinical 
characteristics and outcomes of patients with past and current angina enrolled in 
CORONA, where all patients had ischemic aetiologies(3, 4).  My hypothesis was that 
the presence of angina would be predictive of adverse outcomes when compared with 
patients with no history of angina.  
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3.2 Methods 
The methodology has been described as part of the general methodology section in 
chapter 2 and has therefore not been replicated here.   
3.3 Results 
Of the 4878 patients included in this analysis, 25% (n=1240) had no history of angina, 
28% (n=1353) had a past history of angina and 47% (n=2285) had current angina.  
27% of patients with current angina, reported chest pain on heavy exertion, 49% 
reported chest pain with moderate exertion and 20% reported chest pain with slight 
exertion.  4% of the patients with current angina had pain at rest(3). 
3.3.1 Baseline characteristics (see table 4) 
Comparing patients with past versus no angina (group B vs. group A) 
Patients with past angina were more likely to have a history of prior myocardial 
infarction (70% of patients with past angina vs. 49% with no angina), PCI (17 vs. 9%) 
and CABG (32 vs. 8%).  They were also more likely to have NYHA class III/IV 
symptoms (58 vs. 54%) and be on anti-platelet therapy (61 vs. 53%) or nitrates (28 vs. 
16%) at baseline.  They were less likely to have a history of atrial fibrillation or flutter 
(22 vs. 28%). Other characteristics including age, gender, mean LVEF and treatment 
with ACE inhibitors and beta-blockers were similar between the two groups(3). 
Comparing patients with current versus no angina (group C vs. group A) 
When compared with patients with no angina, those with current angina were more 
likely to be female (27% of patients with current angina vs. 20% with no angina) and 
have a history of prior MI (60 vs. 49%), CABG (17 vs. 8%) and hypertension (71 vs. 
	   54	  
57%).  They were also more likely to experience NYHA class III/IV symptoms (71 vs. 
54%) despite having a lower LVEF (30 vs. 32%) and NT-proBNP (193 vs. 151 
pmol/L).  Patients with no angina were more likely to have atrial fibrillation or flutter 
at baseline(3). 
Comparing patients with current versus past angina (group C vs. group B) 
Patients with current angina were more likely to be female (27% of patients with 
current angina vs. 20% with no angina) and have a history of hypertension (71% vs. 
57%) compared with patients with past angina.  They were also more likely to 
experience NYHA class III/IV symptoms (71% vs. 58%), despite having a higher 
mean LVEF (30% vs. 32%) and a lower median NT-proBNP (187 vs. 151 pmol/L).  
They were less likely to have a history of previous MI (60% vs. 70%), PCI (10% vs. 
17%) or CABG (17% vs. 32%)(3).  
As well as the above differences, patients with no angina were most likely to be 
prescribed anti-coagulant agents, anti-arrhythmic medication and digoxin; they had the 
lowest use of antiplatelet agents and beta-blockers. Patients with current angina were 
least likely to be taking anti-coagulant and anti-arrhythmic drugs at baseline but had 
the highest use of nitrates.  They were also most likely to have a history of diabetes 
mellitus and the highest systolic BP and LVEF(3). 
3.3.2 Clinical outcomes 
CAD outcomes 
When compared to patients with no angina, those with current angina were at higher 
risk of all three coronary composite outcomes (see tables 5 and 6, figure 2).  The risk 
of the composite endpoints of MI, UA or coronary revascularization and MI or UA 
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was approximately twice as high in the current angina group.  This association 
persisted following multivariate analysis.  The risk of the pre-defined ‘coronary’ 
composite endpoint from CORONA was also higher in patients with current angina, 
albeit to a lesser extent(3).   
Patients with past angina were also at higher risk of MI, UA or coronary 
revascularization and MI or UA compared with patients with no angina. The HRs 
were lower (but not statistically different) to those of the current angina group above.  
Patients with past angina were, however, not at higher risk of the pre-defined 
‘coronary’ composite outcome(3). 
HF outcomes 
Patients with current angina were at moderately higher risk of the composite endpoint 
of CV death or HF hospitalization compared to patients with no angina. They were 
also at higher risk of HF hospitalization although the risk of CV death was not 
significantly different to those with no angina. Patients with past angina were not at 
higher risk of CV death or HF hospitalization (or the components of this endpoint) 
compared with patients with no angina (see tables 5 and 6, figure 3)(3).  
Mortality  
The risk of death was not significantly different in patients with past or current angina 
compared with those with no angina (see tables 5 and 6, figure 3). 
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3.4 Discussion 
In almost 5000 patients with HF-REF and CAD in CORONA, 47% had chest pain at 
baseline (presumed to be angina). A number of important differences were noted 
between patients with and without chest pain at baseline. Over 70% of patients with 
current angina were in NYHA functional class III or IV, compared with only 58% of 
patients with past angina and 54% of patients with no angina. This worse functional 
status likely reflected symptomatic myocardial ischaemia rather than severity of HF; 
patients with current angina had the highest blood pressure and LVEF and the lowest 
NT-proBNP levels in keeping with better haemodynamic status(3).  
When comparing the two groups of patients with a history of angina, those without 
current chest pain (i.e. past angina) were more likely to have a history of MI and prior 
coronary revascularisation. This was likely a heterogeneous group of patients and the 
absence of chest pain may have been a reflection of the absence of viable myocardium 
(due to the extent of infarction) or effective revascularization(3). 
Patients with current angina had more than twice as high a risk of ACS, or an ACS 
plus coronary revascularization, as patients with no angina.  Patients with past angina 
were also more likely to experience an ACS than patients with no angina but their risk 
was not as high as patients with current angina. These findings suggest anti-ischemic 
therapy may have the potential to prevent coronary events, as discussed below(3). 
The pre-defined composite ‘coronary’ endpoint from CORONA included 
defibrillation by an ICD, resuscitated cardiac arrest and sudden death.  The risk of this 
endpoint was not as high as that of an ACS in patients with current angina, compared 
to those with no angina (and not increased at all in patients with past angina).  This 
suggests that even in patients with HF sudden death is frequently unrelated to 
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myocardial ischaemia and myocardial scars, rather than active ischaemia, likely 
caused many of the arrhythmic events(3, 108-111).   
In much the same way, the risk of CV and all-cause death was not higher in patients 
with current angina or past angina, compared to patients with no angina. This was 
surprising as it suggests the higher risk of ACS in patients with past and current angina 
was not associated with a higher risk of death due to heart failure or arrhythmia. 
However, even in patients with HF secondary to CAD and current angina, ACS is a 
relatively infrequent occurrence. In our retrospective analysis, a first event of this type 
occurred in approximately 10% of patients, compared with death, which occurred in 
almost 30%, implying that ACS likely only has a small impact on mortality. In 
STICH, at 10-year follow-up patients randomised to CABG had a significant 
reduction in all-cause mortality [HR 0.84 (0.73–0.97); P=0.02](3, 77).  
Interestingly, patients with current angina had a modestly increased risk of HF 
hospitalization compared to patients with no angina.  This was despite patients with 
current angina having a better overall HF risk-profile and suggests myocardial 
ischaemia may have precipitated some HF hospitalizations. In STICH, although 
investigators did not report HF hospitalization, CABG did reduce the composite 
endpoint of all-cause death or HF hospitalization and this persisted at 10-year follow-
up [HR 0.81 (0.71–0.93); P=0.002](3, 77, 81). 
The potential implications of our study are for therapeutic benefit from reducing 
myocardial ischaemia, improving functional status and reducing adverse outcomes 
including coronary events and HF hospitalization. Patients with current angina, with 
the highest rate of ACS and HF hospitalization, likely have the most to gain but 
patients with past angina might also benefit.  As previously discussed, this is a 
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heterogeneous group of patients where more than half had undergone coronary 
revascularization at baseline. The role of CABG in patients with ischaemic 
cardiomyopathy has been demonstrated but the benefits of PCI are still being 
investigated. Pharmacological agents should also be considered, including anti-
thrombotic therapy and anti-ischaemic agents such as nicorandil, which has been 
shown to reduce hospitalization for angina in patients without HF(3, 77, 78, 112). 
There were a number of limitations to our study. The sub-groups used in our study 
were not pre-specified and our findings share the fundamental limitations associated 
with all retrospective analyses. Chest pain at baseline was presumed to be due to 
angina, which may not always have been the case. On the other hand it is recognised 
that myocardial ischaemia can occur in patients with HF, even in patients without 
obstructive coronary artery disease. Finally, the results of coronary angiography were 
not available and the severity of CAD has been independently linked to prognosis(3, 
113).   
3.5 Conclusion 
Symptoms of angina are very common in patients with HF-REF and CAD.  They are 
associated with worse functional class and a higher risk of both ACS and HF 
hospitalization.  This highlights the potential to improve symptoms and outcomes with 
anti-ischaemic therapy but such strategies need to be investigated, ideally with 
randomized controlled-trials(3). 
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Table 4 CORONA: baseline characteristics of groups stratified by history of 
angina and chest pain at baseline. 
 
History of angina 
Current chest pain 
                      
All patients 
 
 
(n=4878) 
Group A 
No 
No 
(n=1240) 
Group B 
Yes 
No 
(n=1353) 
Group C 
Yes 
Yes 
(n=2285) 
 
 
p value for 
trend 
Age yr 72.7 ± 7.1 72.6 ± 7.1 73.1 ± 7.2 72.6 ± 7.0 0.09 
Age ≥70 yr  % 3190 (65.4) 799 (64.4) 911 (67.3) 1480 (64.8) 0.12 
Female % 1148(23.5) 252(20.3) 275(20.3) 621(27.2) <0.01 
NYHA III/IV  % 3069 (62.9) 666 (53.7) 784 (58.0) 1619 (70.9) <0.01 
LVEF (%) 30.9 ± 6.5 30.1 ± 6.7 29.9 ± 6.5 31.8 ± 6.1 <0.01 
Systolic BP mmHg 129.3±16.5 128.9 ±17.1 128.3 ±17.0 130.1 ±15.8 <0.01 
Heart Rate bpm 71.7 ± 11.2 71.9 ± 11.5 71.5 ± 11.5 71.6 ± 10.9 0.64 
BMI kg/m2 27.2 ± 4.5 26.9 ± 4.6 27.0 ± 4.5 27.5 ± 4.5 <0.01 
BMI > median  % 2467 (50.6) 584 (47.1) 673 (49.7) 1210 (53.0) <0.01 
Current smoker % 422 (8.7) 125 (10.1) 133 (9.8) 164 (7.2) <0.01 
Medical History %      
MI 2922 (59.9) 605 (48.8) 948 (70.1) 1369 (59.9) <0.01 
CABG 835 (18.8) 92 (8.0) 377 (31.8) 366 (17.4) <0.01 
PCI 569 (11.7) 109 (8.8) 225 (16.7) 235 (10.3) <0.01 
Diabetes  1443 (29.6) 353 (28.5) 379 (28.0) 711 (31.1) 0.05 
Hypertension 3087 (63.3) 707 (57.0) 769 (56.8) 1611 (70.5) <0.01 
Baseline AF/F 1154 (23.7) 347 (28.0) 297 (22.0) 510 (22.3) <0.01 
Stroke 611 (12.5) 166 (13.4) 174 (12.9) 271 (11.9) 0.19 
Pacemaker 544 (11.2) 148 (11.9) 164 (12.1) 232 (10.2) 0.07 
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ICD 130 (2.7) 34 (2.7) 45 (3.3) 51 (2.2) 0.05 
Lab measurements      
Cholesterol, mmol/l 5.4±1.1 5.3±1.1 5.3±1.1 5.4±1.1 0.02 
Creatinine, µmol/l 115.3±28.0 116.7±28.6 117.9±28.9 113.0±27.0 <0.01 
Median NT-proBNP 
pmol/L (median) 
169.6 193.2 186.6 150.5 <0.01 
Median hs-CRP, 
mg/liter (median) 
3.4 3.7 3.3 3.4 0.27 
Medication      
Loop diuretic 3674(75.3) 968(76.1) 1021(75.5) 1685(73.7) <0.01 
ACE or ARB 4480(91.8) 1155(93.2) 1240(91.7) 2085(91.3) 0.05 
Beta-blocker 3669(75.2) 918 (74.0) 1028(76.0) 1723(75.4) 0.25 
Nitrates 1617(33.1) 200(16.1) 384(28.4) 1033(45.2) <0.01 
Antiarrhythmics 604 (12.4) 173 (14.0) 188 (13.9) 243 (10.6) <0.01 
Antiplatelet 2903(59.5) 659 (53.2) 822 (60.8) 1422(62.2) <0.01 
Anticoagulant 1707(35.0) 505 (40.7) 490 (36.2) 712 (31.2) <0.01 
 
NYHA – New York Heart Association; LVEF – Left Ventricular Ejection Fraction; BMI – 
body mass index; MI – myocardial infarction; PCI – percutaneous coronary intervention; AF – 
atrial fibrillation; ICD – implantable cardio defibrillator; ACE – angiotensin converting 
enzyme inhibitor; ARB – angiotensin receptor blocker. 
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Table 5 CORONA unadjusted analysis: the association between history of angina, 
recent chest pain and clinical outcomes. 
 
Angina history 
Current pain 
Group A 
No 
No 
(n=1240) 
Group B 
Yes 
No 
(n=1353) 
Group C 
Yes 
Yes 
(n=2285) 
 
 
B vs. A 
  
 
C vs. A 
 
 n  
(%) 
n  
(%) 
n  
(%) 
HR  
(95% CI) 
P 
value 
HR  
(95% CI) 
P 
value 
Coronary  
Outcomes 
       
Coronary 
event 
composite§ 
241 
(19.4) 
289  
(21.4) 
580  
(25.4) 
1.10  
(0.92-1.30) 
0.287 1.32  
(1.14-1.54) 
<0.001 
Non-fatal MI, 
UA, PCI or 
CABG 
72 
(5.8) 
115  
(8.5) 
292  
(12.8) 
1.46  
(1.09-1.96) 
0.011 2.23  
(1.72-2.89) 
<0.001 
Non-fatal MI 
or UA 
52 
(4.2) 
93  
(6.9) 
222  
(9.7) 
1.64  
(1.16-2.30) 
0.005 2.33  
(1.73-3.16) 
<0.001 
Heart failure 
Outcomes 
       
CV death or 
HFH 
 
468 
(37.7) 
529  
(39.1) 
902  
(39.5) 
1.02  
(0.90-1.16) 
0.703 1.04  
(0.93-1.17) 
0.458 
CV death 295 
(23.8) 
332  
(24.5) 
514  
(22.5) 
1.02  
(0.87-1.19) 
0.839 0.92  
(0.80-1.06) 
0.269 
HFH  293 
(23.6) 
341  
(25.2) 
621  
(27.2) 
1.06  
(0.90-1.24) 
0.482 1.15  
(1.00-1.32) 
0.050 
All-cause  
death 
379 
(30.6) 
435  
(32.2) 
634  
(27.8) 
1.04  
(0.90-1.19) 
0.611 0.88  
(0.78-1.01) 
0.060 
 
*MI = myocardial infarction; UA = unstable angina; PCI = percutaneous coronary 
intervention; CABG =coronary artery bypass graft surgery; CV = cardiovascular; HFH= heart 
failure hospitalization. § Events included sudden death, fatal or non-fatal MI, PCI, CABG, 
ventricular defibrillation by ICD, resuscitation after cardiac arrest, hospitalization for unstable 
angina.  
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Table 6 CORONA adjusted analysis: the association between history of  
angina, recent chest pain and clinical outcomes. 
 
Angina history 
Current pain 
Group A 
No 
No 
(n=1240) 
Group B 
Yes 
No 
(n=1353) 
Group C 
Yes 
Yes 
(n=2285) 
 
 
B vs. A 
  
 
C vs. A 
 
 n  
(%) 
n  
(%) 
n  
(%) 
HR  
(95% CI) 
P 
value 
HR  
(95% CI) 
P 
value 
Coronary  
Outcomes 
       
Coronary 
event 
composite§ 
241 
(19.4) 
289  
(21.4) 
580  
(25.4) 
1.13 
(0.90-1.43) 
0.290 1.48  
(1.20-1.81) 
<0.001 
Non-fatal MI, 
UA, PCI or 
CABG 
72 
(5.8) 
115  
(8.5) 
292  
(12.8) 
1.62  
(1.07-2.46) 
0.023 2.54  
(1.76-3.68) 
<0.001 
Non-fatal MI 
or UA 
52 
(4.2) 
93  
(6.9) 
222  
(9.7) 
1.94  
(1.21-3.10) 
0.006 2.36 
(1.54-3.61) 
<0.001 
Heart failure 
Outcomes 
       
CV death or 
HFH 
 
468 
(37.7) 
529  
(39.1) 
902  
(39.5) 
1.09  
(0.92-1.27) 
0.354 1.19  
(1.03-1.37) 
0.022 
CV death 295 
(23.8) 
332  
(24.5) 
514  
(22.5) 
0.98  
(0.79-1.20) 
0.831 0.98  
(0.81-1.19) 
0.857 
HFH  293 
(23.6) 
341  
(25.2) 
621  
(27.2) 
1.17  
(0.95-1.44) 
0.137 1.35  
(1.13-1.63) 
0.001 
All-cause  
death 
379 
(30.6) 
435  
(32.2) 
634  
(27.8) 
1.01 
(0.84-1.21) 
0.951 0.97 
(0.82-1.15) 
0.713 
 
*See text of Methods for variables adjusted for.  MI = myocardial infarction; UA = unstable 
angina; PCI = percutaneous coronary intervention; CABG =coronary artery bypass graft 
surgery; CV = cardiovascular; HFH= heart failure hospitalization. § Events included sudden 
death, fatal or non-fatal MI, PCI, CABG, ventricular defibrillation by ICD, resuscitation after 
cardiac arrest, hospitalization for unstable angina.  
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Figure 2 CORONA: Kaplan-Meier curves illustrating the relationship between 
angina history, current chest pain and coronary endpoints. 
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Figure 3 CORONA: Kaplan-Meier curves illustrating the relationship 
between angina history, current chest pain and heart failure outcomes 
and all-cause death.   
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Figure Legends 
 
Figure 2: CORONA: The relationship between angina history, current chest pain and 
coronary endpoints. i) Composite coronary outcome of sudden death, hospitalization 
for UA, fatal/non-fatal MI, coronary revascularization, defibrillation by ICD or 
resuscitation after cardiac arrest (Kaplan-Meier). ii) Composite of non-fatal MI, UA or 
coronary revascularization (Cumulative Incidence Function). iii) Composite of non-
fatal MI or UA (Cumulative Incidence Function).  CR = competing risk. 
  
 
Figure 3: CORONA: The relationship between angina history, current chest pain and 
heart failure outcomes and all-cause death. i) CV death or HF hospitalization (Kaplan-
Meier). ii) CV death iii) HF Hospitalization (Cumulative Incidence Function) iv) All-
cause death (Kaplan-Meier). CR = competing risk. 
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Chapter 4 
 
Clinical Characteristics and Outcomes of Patients with Angina and 
Heart Failure in the CHARM Programme (Candesartan in Heart 
Failure Assessment of Reduction in Mortality and Morbidity)  
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4.1 Introduction 
In CORONA patients with HF-REF and current angina had a higher risk of ACS and 
experienced more functional limitation than patients with no angina. They were also at 
higher risk of HF hospitalization although the risk of all-cause death was similar to 
patients with no angina(3). Little is known of the importance of angina symptoms in 
patients with HF-PEF, which has only previously been investigated in a retrospective 
analysis of the Duke databank for cardiovascular disease.  Patients with angina in the 
Duke databank for cardiovascular disease had a higher risk of the composite endpoint 
of death, MI or coronary revascularization, but other outcomes were not significantly 
different to patients with no angina(98).  To further address these issues a further 
analysis was undertaken examining the outcomes related to angina in patients with 
both HF-PEF and HF-REF from the CHARM trials database(5).  My hypothesis was 
that patients with angina and both heart failure with reduced and preserved ejection 
fractions in CHARM would experience more functional limitation and be at higher 
risk of ACS. 
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4.2 Methods  	  
The methodology has been described as part of the general methodology section in 
chapter 2 and has therefore not been replicated here.   
4.3 Results 
Of the 5408 patients with a history of ischemic heart disease in CHARM, 3855 were 
categorized as having HF-REF: 28.3% of these had no history of angina (n=1092), 
43.2% had past angina (n=1667) and 28.4% had current angina (n=1096).  1553 
patients were classified as having HF-PEF: 21.4% with no history of angina (n=332), 
42.2% with past angina (n= 655) and 36.4% with current angina (n= 566)(5). 
4.3.1 Baseline characteristics 
Comparing patients according to baseline LVEF and angina status  
Tables 7 and 8 summarise the baseline characteristics of patients included in our study 
stratified by LVEF and angina status. 
HF-REF 
When compared with patients with no history of angina, patients with past or current 
angina were more likely to have a history of prior MI, stroke, diabetes mellitus and 
hypertension.  They were also more likely to have undergone coronary 
revascularization at baseline; the highest rates of coronary revascularization were in 
patients with past angina(5).   
Those with current angina also had worse NYHA class and were more likely to report 
symptoms of dyspnea at rest, orthopnea and oedema.  However, patients with current 
angina did not have a lower mean LVEF or systolic BP; they were not at higher risk of 
HF hospitalization and did not have more clinical or radiologic signs of heart failure 
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(with the exception of peripheral oedema which may have reflected higher use of 
vasodilating therapy as detailed below)(5).        
Compared with patients with no angina, patients with past and current angina were 
more likely to be prescribed antiplatelet agents, beta-blockers, lipid-lowering therapy, 
calcium channel blockers, nitrates and other vasodilators at baseline(5).   
HF-PEF 
Patients with HF-PEF and past or current angina were also more likely to have a 
history of hypertension and diabetes and hypertension and to have undergone coronary 
revascularization than patients with no history of angina although the differences were 
not as marked as in patients with HF-REF(5).   
Similarly, patients with HF-PEF and past or current angina had had evidence of 
overall worse heart failure status than patients with no angina. Again this was despite 
the fact that they did not have a lower mean LVEF and were not at higher risk of HF 
hospitalization than patients with no angina (in actual fact, patients with no angina 
were most likely to have a history of HF hospitalization)(5).    
Another similarity trend with the HF-REF group was in the prescription of 
cardiovascular medications.  Patients with past and current angina had higher use of 
lipid-lowering agents, antiplatelets, beta-blockers, calcium channel blockers and other 
vasodilators(5).   
4.3.2 Clinical outcomes 
HF-REF 
All-cause death: There was no difference in the risk of death in patients with past, 
current or no angina (see tables 9 and 10 and Figure 4). 
HF outcomes: There was no significant difference in HF outcomes amongst the three 
groups.  The risk of CV death or HF hospitalization (and the components of this 
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composite endpoint) did not differ between patients with current and no angina.  There 
was a slightly lower risk of CV death when patients with previous angina were 
compared to patients with no angina that just reached statistical significance (HR 0.85, 
0.73-0.99; p=0.040) (see tables 9 and 10 and Figure 4).   
Coronary artery disease outcomes: Patients with current angina were at approximately 
twice as likely to suffer a fatal or non-fatal MI compared to those with no angina.  
This association was still evident after adjusting for other prognostically important 
variables (HR 1.83, 95%CI 1.29-2.60; p=0.001).  Similar relationships were seen with 
regards to MI or UA (adjusted HR 3.13, 2.45-3.98; p<0.001) and the extended 
composite of MI, UA, PCI or CABG (adjusted HR 2.77, 2.23-3.45; p<0.001).   
This higher risk of coronary events was not as marked when patients with past angina 
were compared to those with no angina but still significant for MI or UA (adjusted HR 
1.67, 1.31-2.14; p<0.001) and MI, UA or coronary revascularization (adjusted HR 
1.58, 1.27-1.97; p<0.001) (see tables 9 and 10 and Figure 4)(5).     
HF-PEF 
All-cause death: All-cause death was significantly lower in patients with past and 
current angina compared to those with no angina in the unadjusted analyses.  
However, these associations were not significant after adjustment for other prognostic 
variables (see tables 11 and 12 and Figure 5).    
HF outcomes: In unadjusted analyses patients with past or current angina were at 
lower risk of heart failure outcomes compared with patients with no angina.  Although 
this trend persisted in the adjusted analyses the only statistically significant result 
observed was for the composite heart failure outcomes comparing patients with past 
versus no angina (see tables 11 and 12 and Figure 5).      
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Coronary outcomes: The risk of fatal or non-fatal MI (adjusted HR 1.78, 0.93-3.39; 
p=0.080), MI or UA (adjusted HR 2.75, 1.88-4.01; p<0.001) and MI, UA or coronary 
revascularization (adjusted HR 2.74, 1.96-3.84; p<0.001) were all higher in patients 
with current angina compared with patients with no history of angina.  Although no 
statistically significant differences were seen when comparing patients with past 
versus no angina, the hazard ratios for each coronary outcome were similar to that 
seen in patients with HF-REF (see tables 11 and 12 and Figure 5)(5).    
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4.4 Discussion 
In our analysis of more than 5000 patients with HF secondary to ischemic heart 
disease, 46% of patients with HF-REF had a past history of angina and 28% had 
current angina; in patients with HF-PEF, 43% of patients had past angina and 36% had 
current angina(5).    
Heart failure status  
70% of patients with HF-REF and current angina described NYHA class III or IV 
symptoms, compared with approximately 60% of patients with past or no angina.  
These findings are consistent with those in CORONA where patients with current 
angina were more likely to experience NYHA class III or IV symptoms, despite 
having lower NT proBNP levels and higher LVEFs.  As well as confirming the 
findings from CORONA, CHARM enables us to describe a more complete clinical 
profile of this patient group(3, 5).   
Current angina was also associated with greater levels of dyspnoea and orthopnea.  
However, patients with angina did not have a lower LVEF (as was the case in 
CORONA) or more radiographic or clinical signs of HF (except for peripheral 
oedema).  These consistent findings from both CORONA and CHARM indicate that 
in some patients with HF-REF, common symptoms such as breathlessness and 
functional limitation may occur as a consequence of myocardial ischaemia, rather than 
HF(3, 5).   
In CHARM, I demonstrated similar findings in patients with HF-PEF.  However, in 
the only previous study of patients with angina and HF-PEF, a large retrospective 
single centre analysis from Mentz and colleagues (n=3517), patients with recent 
angina were much less likely to have a high NYHA class (60 vs. 75%).  However, this 
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study examined a highly selected group of patients who had been referred for coronary 
angiography and the lower prevalence of NYHA class III/IV symptoms likely 
reflected better hemodynamic status and less advanced heart failure.  Those with 
angina had lower heart rates, higher blood pressures and were less likely to have 
crepitations or third heart sounds on clinical examination(5, 98).   
Implications of angina on prognosis in HF-REF and HF-PEF 
Although a number of studies have demonstrated angina is not associated with higher 
mortality in patients with HF, little is known of the relationship between angina and 
other outcomes, including coronary events and HF hospitalization(3, 85, 98, 99).  
Moreover, only CORONA examined these associations according to whether angina 
symptoms were past or current. Patients with current angina had a higher risk of MI or 
UA in CORONA (HR 2.36, 1.54-3.61;p <0.001).  These findings were confirmed in 
CHARM where patients with current angina were approximately twice as likely to 
experience a MI and three times as likely to experience any ACS.  A similar 
relationship was seen in patients with HF-PEF and an interaction analysis suggested 
baseline LVEF did not impact upon the association between angina and coronary 
events(3, 5).   
An important difference between this analysis and the previous analysis from 
CORONA is that in CORONA patients with current angina were at higher risk of HF 
hospitalization but no such association was evident in the current study.  Although this 
could be due to chance, there were a number of important differences in the two trials. 
CORONA focused on a much older patient population.  The patients were more likely 
to be prescribed a beta-blocker at baseline (75% of patients in CORONA 75% vs. 56% 
in CHARM) and had lower rates of CABG (19% vs. 34%) and PCI (12% vs. 21%).  
Also I was only able to adjust for prior HF hospitalization in CHARM and not in 
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CORONA; this strong predictor of further HF hospitalization may have influenced our 
results(3, 5).  
One surprising finding in CHARM was that patients with HF-PEF and current angina 
were at lower risk of HF outcomes.  This raises the question as to whether these 
patients truly had HF-PEF and whether instead, coronary disease was responsible for 
their symptoms and limitations(5). 
This analysis in CHARM confirmed the absence of a relationship between past or 
current angina and all-cause mortality in HF-REF.  Again, this was despite the fact 
that they were at higher risk of coronary events when compared with patients with no 
angina(5).   
In CHARM another important finding was that in patients with HF-PEF angina was 
associated with a lower risk of all-cause death, at least in the unadjusted analyses. The 
possible explanation for HF outcomes detailed above might also account for these 
findings(5). 
Clinical implications  
As well as confirming the relationship between current angina with worse functional 
status and a higher risk of ACS in patients with HF-REF, in CHARM I was able to 
demonstrate a similar relationship in patients with HF-PEF.   This further emphasizes 
the importance of investigating whether we can improve outcomes in such patients 
with specific interventions such as target pharmacotherapy or coronary 
revascularization(5).  
Limitations 
The sub-groups examined in my study were not pre-specified and caution should be 
used in interpreting the findings, as is the case with any post-hoc analysis.  A number 
of important exclusion criteria in CHARM such as significant renal impairment and 
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recent coronary events mean the patients in CHARM not fully reflect ‘real-life’ 
cohorts.  Finally the findings of coronary angiography were unavailable; we know 
severity of CAD is independently associated with prognosis and it is difficult to know 
how this information would have impacted upon our findings(5, 117). 
Summary 
Patients with HF with reduced and preserved ejection fractions and angina report more 
functional limitation and breathlessness despite there being no evidence of worse HF 
status.  
They are also at higher risk of coronary events and new prospective studies are needed 
to identify whether specific treatments can improve outcomes in these patients(5).  
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Table 7 CHARM: baseline characteristics of patients with HF-REF stratified by 
history of angina pectoris and current chest pain at baseline. 
 
History of angina 
Current chest pain 
 
Variable 
Group A 
No 
No 
(n=1092) 
Group B 
Yes 
No 
(n=1667) 
Group C 
Yes 
Yes 
(n=1096) 
P Value 
for 
Trend 
 
Age (years) 66.3 (10.1) 66.4 (10.0) 66.6 (9.8) 0.853 
Female sex % 255 (23.4) 370 (22.2) 296 (27.0) 0.013 
Ejection fraction % 30.8 (8.5) 30.8 (8.4) 31.6 (8.5) 0.019 
BMI kg/m2 27.1 (5.0) 27.6 (4.8) 27.9 (4.9) <0.001 
Medical history %     
MI 787 (72.1) 1387 (83.2) 897 (81.8) <0.001 
PCI 125 (11.5) 449 (26.9) 249 (22.7) <0.001 
CABG 219 (20.1) 720 (43.2) 386 (35.2) <0.001 
Hypertension 470 (43.0) 913 (54.8) 588 (53.7) <0.001 
Diabetes Mellitus 303 (27.8) 573 (34.4) 321 (29.3) <0.001 
AF 279 (25.6) 434 (26.0) 224 (20.4) 0.004 
Stroke 89 (8.2) 182 (10.9) 123 (11.2) 0.028 
HF hospitalization 776 (71.1) 1235(74.1) 763 (69.6) 0.028 
Current smoker 185 (16.9) 243 (14.6) 156 (14.2) 0.145 
 Symptoms %     
NYHA III/IV 636 (58.2) 1036(62.2) 762 (69.5) <0.001 
Rest dyspnea. 82 (7.5) 191 (11.5) 180 (16.4) <0.001 
Orthopnea. 153 (14.0) 330 (19.8) 299 (27.3) <0.001 
PND 90 (8.2) 215 (12.9) 115 (10.5) 0.001 
 Examination      
Heart rate bpm 73.5 (12.7) 72.5 (12.2) 71.9(13.1) 0.013 
Systolic BP mmHg 128.3(18.7) 127.9(19.1) 128.7(18.5) 0.579 
Elevated JVP % 74 (6.8) 154 (9.2) 75 (6.8) 0.021 
Oedema % 228 (20.9) 410 (24.6) 347 (31.7) <0.001 
Crackles % 163 (14.9) 304 (18.2) 199 (18.2) 0.053 
S3 gallop % 155 (14.2) 269 (16.1) 256 (14.2) 0.254 
 CXR findings %     
Pulmonary edema 97 (8.9) 180 (10.8) 95 (8.7) 0.107 
Cardiomegaly 247 (22.6) 387 (23.2) 256 (23.4) 0.907 
Pleural effusions 16 (1.5) 20 (1.5) 13 (1.2) 0.795 
 Medications %     
Beta Blockers 562 (51.5) 933 (56.0) 671 (61.2) <0.001 
CCBs 125 (11.5) 269 (16.1) 234 (21.4) <0.001 
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Other vasodilators 343 (31.4) 712 (42.7) 756 (69.0) <0.001 
ACE inhibitors 552 (50.6) 837 (50.2) 527 (48.1) 0.442 
MRA 195 (17.9) 304 (18.2) 182 (16.6) 0.536 
Diuretics 927 (84.9) 1412 (84.7) 925 (84.4) 0.949 
Anticoagulation 369 (33.8) 532 (31.9) 283 (25.8) <0.001 
Anti-platelet agents 674 (61.7) 1138 (68.3) 797 (72.7) <0.001 
Anti-lipid therapies 462 (42.3) 908 (54.5) 572 (52.2) <0.001 
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Table 8 CHARM: baseline characteristics of patients with HF-PEF stratified by 
history of angina pectoris and current chest pain at baseline. 
 
History of angina 
Current chest pain 
 
Variable 
Group A 
No 
No 
(n=332) 
Group B 
Yes 
No 
(n=655) 
Group C 
Yes 
Yes 
(n=566) 
P Value 
for 
Trend 
 
Age (years) 68.7 (9.9) 67.2 (10.4) 66.5 (10.3) 0.008 
Female sex % 117 (35.2) 253 (38.6) 228 (40.3) 0.324 
Ejection fraction % 56.0 (7.8) 56.7 (7.8) 57.1 (8.5) 0.103 
BMI kg/m2 28.4 (5.7) 29.3 (5.7) 28.8 (5.4) 0.033 
Medical history %     
MI 204 (61.5) 373 (57.0) 356 (62.9) 0.090 
PCI 59 (17.8) 173 (26.4) 173 (30.6) <0.001 
CABG 72 (21.7) 248 (37.9) 146 (25.8) <0.001 
Hypertension 206 (62.1) 429 (65.5) 384 (67.8) 0.210 
Diabetes Mellitus 94 (28.3) 208 (31.8) 173 (30.6) 0.541 
AF 103 (31.0) 143 (21.8) 97 (17.1) <0.001 
Stroke 33 (9.9) 48 (7.3) 44 (7.8) 0.346 
HF hospitalization 222 (66.9) 394 (60.2) 333 (58.8) 0.039 
Current smoker 50 (15.1) 86 (13.1) 64 (11.3) 0.260 
 Symptoms %     
NYHA III/IV 122 (36.8) 236 (36.0) 253 (44.7) 0.005 
Rest dyspnea. 19 (5.7) 63 (9.6) 75 (13.3) 0.001 
Orthopnea. 41 (12.4) 133 (20.3) 128 (22.6) 0.001 
PND 28 (8.4) 41 (6.3) 28 (5.0) 0.114 
 Examination      
Heart rate bpm 71.1 (12.6) 70.6 (11.9) 69.7 (11.9) 0.237 
Systolic BP mmHg 137.3(17.7) 135.7(18.6) 134.7(19.1) 0.116 
Elevated JVP % 15 (4.5) 28 (4.3) 23 (4.1) 0.947 
Oedema % 81 (24.4) 194 (29.6) 186 (32.9) 0.028 
Crackles % 66 (19.9) 95 (14.5) 86 (15.2) 0.078 
S3 gallop % 14 (4.2) 32 (4.9) 16 (2.8) 0.182 
 CXR findings %     
Pulmonary edema 28 (8.4) 48 (7.3) 33 (5.8) 0.310 
Cardiomegaly 60 (18.1) 85 (13.0) 71 (12.5) 0.046 
Pleural effusions 3 (0.9) 4 (0.6) 3 (0.5) 0.788 
 Medications %     
Beta Blockers 175 (52.7) 383 (58.5) 367 (64.8) 0.001 
CCBs 93 (28.0) 213 (32.5) 216 (38.2) 0.006 
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Other vasodilators 105 (31.6) 255 (38.9) 376 (66.4) <0.001 
ACE inhibitors 65 (19.6) 133 (20.3) 113 (20.0) 0.963 
MRA 40 (12.1) 59 (9.0) 57 (10.1) 0.324 
Diuretics 239 (72.0) 472 (72.1) 365 (64.5) <0.001 
Anticoagulation 82 (24.7) 132 (20.2) 77 (13.6) <0.001 
Anti-platelet agents 217 (65.4) 492 (75.1) 452 (79.9) <0.001 
Anti-lipid therapies 143 (43.1) 388 (59.2) 281 (49.7) <0.001 
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Table 9 CHARM HF-REF unadjusted analysis: the relationship between history 
of angina, recent chest pain and clinical outcomes. 
 
 
Angina history 
Current pain 
Group A 
No 
No 
(n=1092) 
Group B 
Yes 
No 
(n=1667) 
Group C 
Yes 
Yes 
(n=1096) 
Unadjusted 
B vs. A 
 Unadjusted 
C vs. A 
 
 Number 
(Event 
rate) 
Number 
(Event 
rate) 
Number 
(Event 
rate) 
HR 
(95% CI) 
P value HR (95% CI) P value 
Coronary 
Outcomes 
       
Fatal or non-fatal 
MI 
50  
(1.7) 
103  
(2.3) 
90  
(3.1) 
1.35  
(0.96-1.89) 
0.085 1.80  
(1.28-2.55) 
0.001 
MI or UA 90  
(3.1) 
224  
(5.3) 
256  
(9.8) 
1.67  
(1.31-2.13) 
<0.001 3.09  
(2.43-3.92) 
<0.001 
MI/UA/PCI/ 
CABG 
115  
(4.1) 
269  
(6.4) 
286  
(11.2) 
1.58  
(1.27-1.96) 
<0.001 2.73  
(2.20- 3.39) 
<0.001 
HF Outcomes        
CV death  
or HFH  
406  
(15.0) 
653  
(16.0) 
407  
(15.1) 
1.07  
(0.94-1.21) 
0.314 1.01  
(0.88-1.15) 
0.939 
CV death 286  
(9.5) 
402  
(8.7) 
262  
(8.6) 
0.91  
(0.79-1.06) 
0.249 0.91  
(0.77-1.07) 
0.244 
HF 
hospitalization 
253  
(9.4) 
447  
(11.0) 
258  
(9.6) 
1.17  
(1.00-1.36) 
0.047 1.02  
(0.86-1.22) 
0.808 
All-cause death 335  
(11.2) 
506  
(11.0) 
315  
(10.4) 
0.98  
(0.86-1.13) 
0.804 0.93  
(0.80-1.08) 
0.348 
 
The event rate is the number of events per 100 patient-years of follow-up. 
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Table 10 CHARM HF-REF adjusted analysis: the relationship between history of 
angina, recent chest pain and clinical outcomes. 
  
B vs. A 
  
C vs. A 
 
 HR (95% CI) P value HR (95% CI) P value 
Coronary Outcomes     
Fatal or non-fatal MI* 1.32  
(0.94-1.85) 
0.112 1.83  
(1.29-2.60) 
0.001 
MI or UA* 1.67  
(1.31-2.14) 
<0.001 3.13  
(2.45-3.98) 
<0.001 
MI/UA/PCI/CABG* 1.58  
(1.27-1.97) 
<0.001 2.77  
(2.23-3.45) 
<0.001 
Heart failure Outcomes     
CV death or HFH * 1.00  
(0.88-1.13) 
1.00 1.01  
(0.88-1.16) 
0.929 
CV death* 0.85  
(0.73-0.99) 
0.040 0.88  
(0.74-1.04) 
0.145 
HF hospitalization* 1.08  
(0.93-1.27) 
0.313 1.02  
(0.86-1.21) 
0.837 
All-cause death** 0.96  
(0.84-1.10) 
0.566 0.94  
(0.80-1.10) 
0.417 
 
*Adjusted for: age, diabetes mellitus, LVEF, prior HF hospitalization, cardiomegaly, duration 
of heart failure, NYHA class, diastolic blood pressure, BBB on ECG, heart rate 
**Adjusted for: age, diabetes mellitus, LVEF, prior HF hospitalization, cardiomegaly, NYHA 
class, BBB on ECG, sex, BMI, smoking history 
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Table 11 CHARM HF-PEF unadjusted analysis: the relationship between history 
of angina, recent chest pain and clinical outcomes. 
 
 
Angina history 
Current pain 
Group A 
No 
No 
(n=332) 
Group B 
Yes 
No 
(n=655) 
Group C 
Yes 
Yes 
(n=566) 
Unadjusted 
B vs. A 
 Unadjusted 
C vs. A 
 
 Number 
(Event 
rate) 
Number 
(Event 
rate) 
Number 
(Event 
rate) 
HR 
(95% CI) 
P value HR (95% CI) P value 
Coronary 
Outcomes 
       
Fatal or non-fatal 
MI 
13  
(1.4) 
29  
(1.5) 
36  
(2.2) 
1.12  
(0.58-2.15) 
0.734 1.59  
(0.84-3.00) 
0.151 
MI or UA 34  
(3.8) 
93  
(5.2) 
146  
(10.4) 
1.39  
(0.94-2.06) 
0.101 2.71  
(1.86-3.93) 
<0.001 
MI/UA/PCI/ 
CABG 
43  
(4.9) 
110  
(6.3) 
182  
(13.6) 
1.29  
(0.91-1.83) 
0.158 2.73  
(1.96-3.80) 
<0.001 
HF Outcomes        
CV death  
or HFH  
91  
(10.5) 
130  
(7.3) 
118  
(7.7) 
0.70  
(0.54-0.92) 
0.009 0.74  
(0.56-0.97) 
0.032 
CV death 48  
(5.1) 
63  
(3.3) 
55  
(3.3) 
0.65  
(0.44-0.94) 
0.023 0.64  
(0.44-0.95) 
0.026 
HF 
hospitalization 
65  
(7.5) 
94  
(5.3) 
83  
(5.4) 
0.71  
(0.52-0.98) 
0.036 0.73  
(0.53-1.01) 
0.061 
All-cause death 70  
(7.4) 
91  
(4.7) 
76  
(4.5) 
0.64  
(0.47-0.87) 
0.005 0.61  
(0.44-0.84) 
0.003 
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Table 12 CHARM HF-PEF adjusted analysis: the relationship between history of 
angina, recent chest pain and clinical outcomes. 
 
  
B vs. A 
  
C vs. A 
 
 HR (95% CI) P value HR (95% CI) P value 
Coronary Outcomes     
Fatal or non-fatal MI* 1.15  
(0.59-2.23) 
0.677 1.78  
(0.93-3.39) 
0.080 
MI or UA* 1.40  
(0.94-2.08) 
0.096 2.75  
(1.88-4.01) 
<0.001 
MI/UA/PCI/CABG* 1.28  
(0.89-1.82) 
0.180 2.74  
(1.96-3.84) 
<0.001 
Heart failure Outcomes     
CV death or HFH * 0.75  
(0.57-0.98) 
0.037 0.81  
(0.61-1.07) 
0.129 
CV death* 0.70  
(0.48-1.03) 
0.069 0.71  
(0.48-1.05) 
0.089 
HF hospitalization* 0.77  
(0.56-1.07) 
0.115 0.80  
(0.57-1.12) 
0.192 
All-cause death** 0.77  
(0.56-1.05) 
0.101 0.72  
(0.52-1.01) 
0.058 
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Figure 4 CHARM: The relationship between angina and clinical endpoints (HF-REF)
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Figure 5 CHARM: The relationship between angina and clinical endpoints (HF-PEF) 
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Figure 4: Kaplan-Meier curves illustrating the relationship between angina and 
clinical endpoints in patients with HF-REF in CHARM. i) Fatal or non-fatal 
myocardial infarction (MI) ii) Composite of MI or unstable angina (UA) iii) 
Composite of MI, UA, percutaneous coronary intervention (PCI) or coronary artery 
bypass graft surgery (CABG) iv) Heart failure (HF) hospitalization v) Composite of 
cardiovascular (CV) death or HF hospitalization vi) All-cause death. 
  
 
Figure 5: Kaplan-Meier curves illustrating Kaplan-Meier curves illustrating the 
relationship between angina and clinical endpoints in patients with HF-PEF in 
CHARM. i) Fatal or non-fatal myocardial infarction (MI) ii) Composite of MI or 
unstable angina (UA) iii) Composite of MI, UA, percutaneous coronary intervention 
(PCI) or coronary artery bypass graft surgery (CABG) iv) Heart failure (HF) 
hospitalization v) Composite of cardiovascular (CV) death or HF hospitalization vi) 
All-cause death.                
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Chapter 5 
Clinical Characteristics and Outcomes of Patients with Coronary 
Artery Disease and Angina: An analysis of the I-PRESERVE trial 
(Irbesartan in Heart Failure with Preserved Ejection Fraction Study). 
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5.1 Introduction 
Studies examining the relationship between CAD and prognosis in HF-PEF have 
produced conflicting results(58, 118-120).  Even less is known about the importance of 
angina in these patients, which has only been the focus of two previous analyses(5, 
98).  In this analysis of the I-PRESERVE trial we looked to expand on the current 
literature by exploring the relationship between CAD, angina and outcomes in a large 
HF-PEF population.  I also examined the individual components of all-cause mortality 
to try and further understand the mechanisms by which the presence or absence of 
CAD angina and CAD might affect prognosis(7).  My hypothesis was that the 
presence of CAD and angina would be associated with a higher risk of adverse clinical 
outcomes.   
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5.2 Methods 
The methodology has been described as part of the general methodology section 
in chapter 2 and has therefore not been replicated here.   
5.3 Results 
Baseline characteristics 
Baseline characteristics are presented in table 13.   
Comparison of patients with a history of CAD (groups C and D) vs. patients without 
a history of CAD (groups A and B)   
When compared with patients without a history of CAD, Patients with a history of 
CAD had lower mean LVEFs (59/57 vs. 61/60% in groups C and D vs. groups A and 
B), were more likely to experience NYHA class III or IV symptoms (82/81 vs. 
78/76%), and had higher median NT-pro BNP levels (455/454 vs. 298/241).  They 
were more likely to be male (56/51 vs. 34/30%), have a history of stroke (13/10 vs. 
9/9%) and diabetes (38/29 vs. 26/22%) and be prescribed anti-platelets (74/81 vs. 
42/65%) or ACE inhibitors (30/29 vs. 22/26%) at baseline.   
Patients without a history of CAD were more likely to have a history of hypertension 
(91/96 vs. 81/82%) and be prescribed CCBs at baseline (43/44 vs. 31/36%)(7).   
Comparison of patients with no history of CAD or angina vs. patients with no 
history of CAD but a history of angina 
When comparing patients without a history of CAD, a number of important 
differences were noted in those with and without angina.  Despite those with a history 
of angina having less NYHA class III or IV symptoms (76 vs. 78%) and lower NT-pro 
BNP levels (241 vs. 298), their quality of life as assessed by the Minnesota living with 
HF questionnaire was lower (score of 45 vs. 41).  Mean LVEFs was similar between 
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the two groups.  Patients with angina were also more likely to be female (70 vs. 66%), 
Caucasian (98 vs. 91%) and have a history of hypertension (96 vs. 90%).  They were 
less likely to have diabetes (22 vs. 26%) or AF (13 vs. 20%)(7).   
Comparison of patients with a history of CAD but no angina vs. patients with a 
history of CAD and angina 
Patients with a history of CAD and angina had lower mean LVEFs (57 vs. 59%), 
worse quality of life scores (Minnesota living with HF score of 45 vs. 41) and were 
less likely to have a history of diabetes (29 vs. 38%) or previous coronary 
revascularization (35 vs. 43%).  They were more likely to be prescribed diuretics, 
BBs, CCBs, nitrates and anti-platelets at baseline.  NT-pro BNP levels (445 vs. 455), 
the proportion of patients with NYHA class III or IV symptoms (82 vs. 81%), and the 
percentage of patients with previous MIs (66% in both groups) or hypertension (82 vs. 
81%) was similar between the two groups(7). 
Clinical Outcomes 
Mortality outcomes   
Cardiovascular death accounted for 70% of all deaths in I-Preserve. Sudden death was 
the most common cause of cardiovascular death accounting for 38% (n=231) of cases; 
almost twice as many as the number of deaths due to HF (20% of all cardiovascular 
deaths, n=125). 
When examining patients without a history of CAD, the only significant difference in 
patients with and without angina was a lower risk of death due to HF in patients with 
angina in the unadjusted analysis.  However this association was no longer significant 
after adjusting for prognostically important covariates (HR 0.54 (0.24-1.21); p=0.135) 
(see figure 6 and tables 14-16).  
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In both adjusted and unadjusted analyses patients with a history of CAD were at 
higher risk of all-cause death with the highest risk in patients with a history of CAD 
and no history of angina  (adjusted HR 1.58 (1.22-2.04); p<0.001).  There was also an 
association with higher CV death (HR 1.50 (1.10-2.06); p=0.011) and sudden death 
(HR 2.15 (1.35-3.44); p=0.001) but no significant difference was seen in pump failure 
deaths (HR 0.66 (0.29-1.49); p=0.315).  Patients from group D there were also at 
higher risk of all-cause mortality (HR 1.29 (1.05-1.59); p=0.016), CV death (HR 1.46 
(1.14-1.86); p=0.002) and sudden death (HR 1.83 (1.24-2.69); p=0.002), albeit to a 
lesser extent than patients in group C(7).   
HF outcomes  
In patients with no history of CAD, the risk of heart failure outcomes was similar in 
those with and without angina (see tables 14-16 and Figure 7).  Although there was a 
lower risk of HF hospitalization in patients with a history of angina in the unadjusted 
analysis, this was not significant after accounting for prognostically important 
variables in the adjusted analysis (HR 0.94 [0.70–1.25]; P=0.67). 
When compared with patients with no history of CAD or angina, patients with a 
history of CAD (both those with or without angina) had a higher risk of HF 
hospitalization and the composite end point of HF death or HF hospitalization in the 
unadjusted analysis.  However, in the adjusted analysis the only statistically significant 
finding was the risk of HF death or HF hospitalization in patients with CAD and 
angina (HR, 1.26 [1.03–1.54]; P=0.02; Tables 14-16; Figure 7)(7). 
Coronary outcomes 
In I-Preserve coronary events were relatively infrequent, with only 5% of the study 
population hospitalized for MI or UA over the follow-up period.  
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In both adjusted and unadjusted analyses patients with no history of CAD but a history 
of angina were at elevated risk of UA or MI compared with patients with no history of 
CAD or angina (adjusted HR, 2.20 [1.10–4.37]; P=0.03). However, their risk of fatal 
or nonfatal MI was not significantly different to patients with no history of CAD or 
angina.   
Patients with CAD but no history of angina and patients with CAD and angina were 
both at elevated risk of UA or MI when compared with patients with no history of 
CAD or angina. Both groups were also at higher risk of fatal or nonfatal MI in the 
adjusted analyses ([HR, 2.75 ; P=0.01] and [HR, 5.14 ; P<0.01]; Tables 14-16; Figure 
7)(7). 
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5.4 Discussion 
In this study, 68% of patients with HF-PEF and CAD had a history of stable angina 
pectoris compared with 24% of those without CAD.  The high frequency of angina 
symptoms in patients without a known history of CAD is in keeping with the findings 
of a retrospective study of 376 patients hospitalized with HF-PEF in North America.  
In that analysis, all patients underwent diagnostic coronary angiography and a similar 
prevalence of angina was reported regardless of whether or not significant epicardial 
CAD was identified(58). Other factors such as microvasculature dysfunction may 
therefore have contributed to angina symptoms in patients without epicardial 
CAD(125). In our analysis it is also possible that some patients had undiagnosed 
CAD.  I did not have access to coronary angiography data but 3% of patients went on 
to have an ACS during follow-up(7).  
Baseline characteristics 
Patients with CAD had evidence of more advanced heart failure with a higher 
frequency of NYHA class III or IV symptoms, higher NT pro BNP levels and lower 
LV ejection fractions. However quality of life as assessed by the Minnesota Living 
with Heart failure questionnaire was not significantly different to those without CAD.  
A history of angina pectoris, on the other hand, had a significant negative impact on 
quality of life, irrespective of whether patients had a history of CAD.  In I-
PRESERVE investigators did not differentiate patients with past or current angina, but 
these findings suggest there may be potential to improve quality of life in patients with 
HF-PEF by targeting symptoms of angina pectoris(7).    
The relationship between CAD, angina and mortality outcomes. 
Few studies have examined the interaction between CAD and all-cause mortality in 
patients with HF-PEF.  CAD was associated with higher all-cause mortality in one 
	   95	  
single-centre study of 376 patients with HF hospitalizations due to HF-PEF (adjusted 
HR, 1.71 [1.03–2.98];p=0.04) and in patients with HF-PEF from the CASS Registry 
(n=284)(58, 120).  However, there was no such association in a prospective 
multicentre study of patients hospitalized with HF-PEF in France (n=320) and a cohort 
of 220 patients with HF-PEF from the Framingham Study(118, 119).  The reasons for 
these conflicting findings are not clear but most likely a consequence of the 
heterogeneity of the populations studied as well as the differences in how CAD was 
defined.  In this analysis of I-Preserve, patients with a history of CAD (with and 
without angina) were at higher risk of death than patients with no history of CAD or 
angina(7). 
Arguably the most important finding in this analysis was the significantly higher risk 
of sudden death in patients with CAD.  This supports the previous findings from two 
small, retrospective analyses of patients discharged from hospital with a diagnosis of 
HF-PEF where CAD was also associated with a higher risk of sudden death(118, 126).  
Presumably, CAD increases the rate of sudden death by precipitating ventricular 
arrhythmias.  Perhaps surprisingly the highest risk was in patients with CAD but 
without a history of angina (HR 2.15 (1.35-3.44); p=0.001).  Patients with CAD and 
angina (HR, 1.83 [1.24–2.69]; P<0.01) were at also at higher risk, albeit to a lesser 
extent.  This was despite patients with CAD and angina having a relatively higher risk 
of acute coronary syndromes (UA/MI HR 4.44 (2.31-8.54); p<0.001 vs. 5.84 (3.43-
9.95); p<0.001).  This suggests the majority of sudden death (and presumably 
arrhythmogenic deaths) were not precipitated by active ischaemia, either in the acute 
or chronic settings.  Silent ischaemia may have been a factor but this is outwith the 
remit of my thesis and there is no data to confirm or refute its potential impact on our 
findings.  Finally, it is possible the absence of angina was a marker of more ‘scarred’ 
myocardium with an increased propensity to promote arrhythmia and sudden death(7).  
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Whilst patients with CAD and HF-PEF are at higher risk of sudden cardiac death, the 
absolute rate is still low and the role of implantable cardioverter defibrillators is not 
clear. A planned study of implantable loop recorders in patients with HF-PEF intended 
to ascertain the frequency of ventricular arrhythmias in this population will exclude 
patients with significant CAD or recent MI and is therefore unlikely to fully answer 
this question (http://clinicaltrials.gov/ct2/show/NCT01989299)(7). 
The relationship between CAD, angina and non-fatal outcomes. 
In patients with CAD and HF-PEF from CHARM there was a clear relationship 
between current angina and ACS(5). In I-Preserve, although patients with CAD and a 
history of angina were at elevated risk of UA/MI (HR 5.84 (3.43-9.95); p<0.001), the 
relative increase when compared to that seen in the group with CAD but no history of 
angina (HR 4.44 (2.31-8.54); p<0.001) was relatively modest.  In I-PRESERVE, 
although investigators detailed a history of stable angina, patients with past and 
current angina were not differentiated.  This may have diluted the association.  
Nevertheless these results do highlight the importance of investigating whether 
specific medical therapies or coronary revascularization might have a role to play in 
reducing adverse outcomes in subgroups of patients with HF-PEF(7).   
Again a number of limitations should be considered.  Our analysis was not pre-
specified and our results have the same limitations of all post hoc analysis.  Also, I-
PRESERVE only enrolled patients over 60 years of age and our findings cannot be 
generalized to all patients with HF-PEF.  Finally patients did not undergo routine 
screening for CAD and it is possible that patients with CAD may have been 
misclassified (or vice versa)(7).      
In conclusion, patients with HF-PEF and CAD have evidence of more advanced HF 
whereas patients with angina and HF-PEF experience poorer quality of life 
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irrespective of whether they have underlying CAD.  Patients underlying CAD are at 
higher risk of sudden death and our findings highlight the need to investigate whether 
interventions such as specific medical therapies, coronary revascularization or ICDs 
might improve outcomes(7).  
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Table 13 I-Preserve: baseline characteristics of patients with HF-PEF stratified 
by history of coronary artery disease and angina. 
 
Hx of CAD 
Hx of Angina 
 
Variable 
All 
 
 
(n=4128) 
Group A 
No 
No 
(n=2008) 
Group B 
No 
Yes 
(n=649) 
Group C 
Yes 
No 
(n=468) 
Group D 
Yes 
Yes 
(n=1003) 
 
 
 
 
p value 
Age 71.6  
± 6.9 
71.8  
± 7.1 
71.0  
± 6.7 
72.6  
± 7.0 
71.3  
± 6.8 
<0.001 
Female 2491  
(60.3%) 
1330 
(66.2) 
455 
(70.1%) 
214  
(45.7) 
492  
(49.1) 
<0.001 
Caucasian race 3859  
(93.5%) 
1835 
(91.4%) 
634 
(97.7%) 
435 
(93.0%) 
955 
(95.2%) 
<0.001 
NYHA III/IV 3257  
(78.9%) 
1563 
(77.8%) 
492 
(75.8%) 
385 
(82.3%) 
817 
(81.5%) 
0.007 
Minnesota  
HF score 
42.7  
(20.7) 
41.2 
(21.0) 
45.6 
(18.5) 
41.1 
(21.9) 
44.5 
(20.9) 
<0.001 
LVEF (%) 59.4  
± 9.2 
60.6  
± 9.5 
60.1  
± 8.5 
58.6  
± 9.4 
57.0  
± 8.1 
<0.001 
Systolic BP 
(mm/Hg) 
136.3  
± 15.0 
137.3  
± 15.3 
137.2 
±13.4 
134.6 
±16.3 
134.8 
±14.5 
0.004 
Heart Rate 71.4  
± 10.4 
71.9  
± 10.8 
71.3 
 ± 9.5 
70.9  
± 10.6 
70.8  
± 10.1 
0.017 
BMI kg/m2 29.6   
± 5.3 
30.0  
± 5.6 
29.4  
± 4.8 
29.3  
± 5.1 
29.2  
± 4.9 
<0.001 
Medical Hx       
MI 969  
(23.5%) 
0  
(0%) 
0  
(0%) 
308 
(65.8%) 
661 
(65.9%) 
<0.001 
PCI or CABG 548  
(13.3%) 
0  
(0%) 
0  
(0%) 
200 
(42.7%) 
348 
(34.7%) 
<0.001 
Hypertension 3650  
(88.4%) 
1823 
(90.8%) 
622 
(95.8%) 
380 
(81.2%) 
825 
(82.3%) 
<0.001 
Diabetes 
Mellitus 
1134  
(27.5%) 
520 
(25.9%) 
145 
(22.3%) 
179 
(38.3%) 
290 
(28.9%) 
<0.001 
AF at baseline 670  
(16.2%) 
401 
(20.0%) 
81 
(12.5%) 
70 
(15.0%) 
118 
(11.8%) 
<0.001 
Stroke or TIA 399  
(9.7%) 
178 
(8.9%) 
56  
(8.6%) 
61 
(13.0%) 
104 
(10.4%) 
0.030 
Pacemaker 252  122  35  37  58  0.333 
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(6.1%) (6.1%) (5.4%) (7.9%) (5.8%) 
ICD 12  
(0.3%) 
3  
(0.2%) 
1  
(0.2%) 
3  
(0.6%) 
5  
(0.5%) 
0.153 
Lab 
measurements 
      
 Anaemia 514  
(12.9%) 
239 
(12.5%) 
60  
(9.4%) 
72 
(16.0%) 
143 
(14.6%) 
0.003 
 GFR 72.5  
± 22.5 
72.5  
± 23.1 
72.8  
± 19.8 
70.4  
± 21.3 
73.4  
± 23.3 
0.126 
Median NT-
pro BNP  
339 298 241 455 454.5 0.005 
Medication       
Loop diuretic 
or thiazide  
3418  
(82.9%) 
1639 
(81.6%) 
576 
(88.9%) 
357 
(76.3%) 
846 
(84.5%) 
<0.001 
ACE inhibitor 1033  
(25.0%) 
438 
(21.8%) 
167 
(25.8%) 
139 
(29.7%) 
289 
(28.9%) 
<0.001 
Beta-blocker 2427  
(58.8%) 
1016 
(50.6%) 
434 
(67.0%) 
296 
(63.3%) 
681 
(68.0%) 
<0.001 
CCBs 1637  
(39.7%) 
857 
(42.7%) 
282 
(43.5%) 
143 
(30.6%) 
355 
(35.5%) 
<0.001 
Long-acting 
Nitrate 
1108  
(26.9%) 
186 
(9.3%) 
245 
(37.8%) 
135 
(28.9%) 
542 
(54.2%) 
<0.001 
Antiplatelet 2416  
(58.6%) 
843 
(42.0%) 
422 
(65.1%) 
344 
(73.5%) 
807 
(80.6%) 
<0.001 
 Statin 1210  
(29.3%) 
459  
(22.9) 
150  
(23.1) 
229  
(48.9) 
372  
(37.1) 
<0.001 
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Table 14 I-PRESERVE: event rates of patients with HF-PEF stratified by  
history of coronary artery disease and angina. 
Group  
 
History of CAD 
History of angina 
A 
 
No 
No 
B 
 
No 
Yes 
C 
 
Yes 
No 
D 
 
Yes 
Yes 
 
 
 
(n=2008) 
 
(n=649) 
 
 
(n=468) 
 
(n=1003) 
Mortality outcomes     
All-cause death 379 (18.9) 110 (16.9) 153 (32.7) 239 (23.8) 
CV death 243 (12.1) 
 
83 (12.8) 
 
104 (22.2) 
 
183 (18.2) 
 
Sudden death 83 (4.1) 31 (4.8) 43 (9.2) 74 (7.4) 
Pump failure death 61 (3.0) 10 (1.5) 18 (3.8) 36 (3.6) 
Heart Failure 
Outcomes 
    
HF composite 390 (19.4) 106 (16.3) 126 (26.9) 244 (24.3) 
HF hospitalization 312 (15.5) 81 (12.5) 88 (18.8) 180 (17.9) 
Coronary Outcomes     
Fatal/non-fatal MI 
 
33 (1.6) 14 (2.2) 25 (5.3) 77 (7.7) 
UA/MI 
 
41 (2.0) 20 (3.1) 33 (7.1) 100 (10.0) 
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 Table 15 I-PRESEVE unadjusted analysis: the relationship between  
history of coronary artery disease and angina with clinical outcomes. 
 
  
Group  
 
History of CAD 
History of angina 
 
B vs. A 
 
C vs. A 
 
D vs. A 
 
 
 
HR  
(95% CI) 
 
P value 
 
HR  
(95% CI) 
 
P value 
 
HR  
(95% CI) 
 
P value 
Mortality outcomes       
All-cause death 0.85  
(0.69-1.05) 
 
0.135 1.90  
(1.57-2.29) 
<0.001 
 
1.30  
(1.10-1.52) 
 
0.002 
 
CV death 1.00  
(0.78-1.29) 
 
0.973 
 
2.00  
(1.59-2.52) 
 
<0.001 
 
1.55  
(1.28-1.88) 
<0.001 
 
Sudden death 1.10  
(0.73-1.66) 
0.657 2.42  
(1.67-3.49) 
<0.001 1.83  
(1.34-2.50) 
<0.001 
Pump failure death 0.48  
(0.25-0.95) 
0.034 1.38  
(0.81-2.33) 
0.235 1.22  
(0.81-1.84) 
0.351 
Heart Failure 
Outcomes 
      
HF composite 0.81  
(0.65-1.00) 
0.051 1.49  
(1.22-1.82) 
<0.001 1.31  
(1.12-1.54) 
0.001 
HF hospitalization 0.78  
(0.61-0.99) 
0.041 1.29  
(1.02-1.64) 
0.033 1.21  
(1.00-1.45) 
0.045 
Coronary Outcomes       
Fatal/non-fatal MI 1.26  
(0.68-2.36) 
0.464 3.52  
(2.09-5.92) 
<0.001 4.89  
(3.25-7.35) 
<0.001 
UA/MI 
 
1.46  
(0.86-2.49) 
0.166 3.75  
(2.37-5.93) 
<0.001 5.16  
(3.59-7.43) 
<0.001 
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Table 16 I-PRESEVE adjusted analysis: the relationship between history of  
coronary artery disease and angina with clinical outcomes. 
 
  
Group  
 
History of CAD 
History of angina 
 
B vs. A 
 
C vs. A 
 
D vs. A 
 
 
 
HR  
(95% CI) 
 
P value 
 
HR  
(95% CI) 
 
P value 
 
HR  
(95% CI) 
 
P value 
Mortality outcomes       
All-cause death 0.95  
(0.73-1.25) 
 
0.716 1.58  
(1.22-2.04) 
<0.001 
 
1.29 
(1.05-1.59) 
 
0.016 
 
CV death 1.11  
(0.82-1.52) 
 
0.502 
 
1.50  
(1.10-2.06) 
 
0.011 
 
1.46  
(1.14-1.86) 
0.002 
 
Sudden death 1.09  
(0.64-1.86) 
0.751 2.15  
(1.35-3.44) 
0.001 1.83  
(1.24-2.69) 
0.002 
Pump failure death 0.54  
(0.24-1.21) 
0.135 0.66  
(0.29-1.49) 
0.315 1.08  
(0.641.83) 
0.775 
Heart Failure 
Outcomes 
      
HF composite 0.93  
(0.72-1.20) 
0.557 1.19  
(0.91-1.55) 
0.196 1.26  
(1.03-1.54) 
0.023 
HF hospitalization 0.94  
(0.70-1.25) 
0.667 1.03  
(0.75-1.40) 
0.873 1.12  
(0.89-1.41) 
0.347 
Coronary Outcomes       
Fatal/non-fatal MI 1.51  
(0.66-3.43) 
0.327 2.75  
(1.26-5.97) 
0.011 5.14  
(2.90-9.13) 
<0.001 
UA/MI 
 
2.20  
(1.10-4.37) 
0.025 4.44  
(2.31-8.54) 
<0.001 5.84 
(3.43-9.95) 
<0.001 
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Figure 6: I-Preserve Kaplan-Meier curves illustrating the relationship between 
angina history, CAD and mortality endpoints  
I   
 
 
II   
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III   
IV  
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Figure 7:I-Preserve Kaplan-Meier curves illustrating the relationship between  
angina history, CAD and non-fatal outcomes.  
I   
II  
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III  
IV  
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Figure 6: I-Preserve Kaplan-Meier curves illustrating the relationship between  
angina history, CAD and mortality endpoints. i) All-cause death ii) CV death  
iii) Sudden death iv) Death due to heart failure 
  
 
Figure 7: I-Preserve Kaplan-Meier curves illustrating the relationship between  
angina history, CAD and non-fatal outcomes. i) I-Preserve HF composite ii) HF 
Hospitalization iii) Fatal or non-fatal myocardial MI iv) MI or unstable angina  
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Chapter 6 
The relationship between severity of angina and outcomes in patients with heart 
failure and reduced ejection fraction in the Prospective comparison of ARNI with 
ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure 
(PARADIGM-HF) trial. 
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6.1 Introduction 
I previously examined the prognostic importance of angina in patients with HF-REF. 
In retrospective analyses from CORONA and CHARM, patients with HF-REF and 
current angina experienced greater functional limitation and were at higher risk of 
coronary events than those with no history of angina.  However, current angina was not 
associated with higher all-cause mortality in these analyses, in a prior analysis of the 
COMET trial, the STICH trial or a large single centre study from North America 
(n=2376)(3, 5, 85, 99, 127).  
I therefore utilized the Prospective comparison of Angiotensin Receptor-neprilysin 
inhibitor with Angiotensin-converting–enzyme inhibitor to Determine Impact on 
Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) to examine 
the relationship between severity of angina and outcomes in patients with HF-REF(9).  
My hypothesis was that more severe angina would be predictive of mortality, as well 
as non-fatal outcomes, compared with less severe angina. 
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6.2 Methods 
The methodology has been described as part of the general methodology section 
in chapter 2 and has therefore not been replicated here.   
6.3 Results 
Of 8842 patients in PARADIGM-HF, 5594 had a history of CAD. Of the patients with 
CAD, 1725 (31%) reported angina at baseline; of these, 447 (8% of the patients with 
CAD) had mild angina, 884 (16%) moderate angina and 394 (7%) severe angina. 
Baseline characteristics 
Baseline characteristics stratified by severity of angina symptoms are presented in 
Table 17. Patients with angina of any severity were more likely to be female, 
Caucasian and older than those with no angina. They also more frequently had a 
history of prior MI, hypertension and atrial fibrillation, but not diabetes or stroke. 
Patients with mild angina had received more interventions, including percutaneous 
coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery and a 
pacemaker, cardiac resynchronization therapy (CRT) or an implantable cardioverter 
defibrillator (ICD) compared to those with either no angina or moderate or severe 
angina. They also had the highest use of beta-blockers, statins and anti-platelet agents. 
Compared to those with no angina, patients with moderate or severe angina had a 
higher mean LVEF but worse symptoms and signs of HF, including paroxysmal 
nocturnal dyspnoea, pulmonary crackles and peripheral oedema and a higher 
proportion of these patients were in NYHA functional classes III and IV. Their mean 
KCCQ score was also lower (worse) than in patients with no angina. Patients with 
moderate or severe angina were less likely to have a pacemaker, ICD or CRT.   
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Patients with severe angina were most likely to be in NYHA functional class III or IV 
and experience dyspnoea at rest, paroxysmal nocturnal dyspnoea and fatigue.  They 
had the lowest KCCQ scores and the highest median NT-proBNP levels, despite 
having the highest mean LVEF. They were also most likely to have experienced a 
previous MI but least likely to have undergone PCI or ICD implantation.    	  
Clinical Outcomes 
CV death or HF hospitalization (the primary endpoint of PARADIGM-HF) 
There was no relationship between the presence of mild or moderate angina and the 
composite endpoint of CV death or HF hospitalization, or with its components (Tables 
18-19; Figure 8).  
By contrast, patients with severe angina were at significantly higher risk of CV death 
or HF hospitalization (adjusted HR 1.41, 1.17-1.70; p<0.01) and CV death alone 
(adjusted HR 1.60, 1.27-2.01; p<0.01), when compared to those with no angina at 
baseline.  There was also an association between severe angina and a higher risk of HF 
hospitalization in the univariate analysis but this was no longer significant after 
adjusting for other covariates (adjusted HR 1.27, 0.98-1.64; p=0.07) (Tables 18-19; 
Figure 8).   
Coronary events 
The risk of coronary events (hospitalization for UA, hospitalization for non-fatal MI, 
hospitalization for UA or non-fatal MI and fatal or non-fatal MI) was not significantly 
different in patients with mild versus no angina at baseline.  Patients with moderate 
angina were at higher risk of UA (adjusted HR 2.02, 1.15-3.53; p=0.01) but their risk 
of MI was not significantly higher than in patients with no angina. Patients with severe 
angina were at higher risk for all adverse coronary outcomes, having an approximately 
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six-fold higher risk of hospitalization for UA (adjusted HR 5.81, 3.28-10.28; p<0.01) 
and being almost twice as likely to experience a fatal or non-fatal MI (adjusted HR 
1.90, 1.18-3.06; p=0.01). 
Mortality 
Compared to those with no angina, patients with severe angina were at significantly 
higher risk of all-cause mortality (adjusted HR 1.48, 1.20-1.84; p<0.01; Figure 8), CV 
mortality (see above) and sudden death (adjusted HR 1.86, 1.35-2.57; p<0.01; Figure 
8). However their risk of death due to HF was not significantly higher than those with 
no angina (adjusted HR 1.32, 0.80-2.17; p=0.28; Tables 18-19; Figure 8).  Patients 
with mild or moderate angina were not at higher risk of all-cause or CV mortality (or 
any of the modes of CV death) compared to those with no angina.   
The effect of LCZ696 versus enalapril according to angina status was not significantly 
different for any of the aforementioned endpoints.  
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6.4 Discussion 
In our analysis of 5594 patients with CAD from PARADIGM-HF, 31% of patients 
reported angina at baseline; symptoms were mild in 8% of patients, moderate in 16% 
and severe in 7%. Severe angina symptoms were associated with significantly more 
functional limitation and a higher risk of the composite outcome of CV death or HF 
hospitalization, non-fatal MI and CV as well as all-cause death.   
Baseline characteristics 
There was a strong association between greater severity of angina and worse 
functional status in PARADIGM-HF. More than two thirds of patients with severe 
angina were in NYHA functional class III or IV compared with approximately 40% of 
those with moderate angina and just 20% of patients with mild or no angina. Two of 
our studies also demonstrated a relationship between the presence of any angina and 
worse functional class but the association in those studies was much weaker (although 
they did not grade the severity of angina). In CORONA 71% of patients with current 
angina reported NYHA class III or IV symptoms compared to 54% of patients with no 
angina; in CHARM 70% of those with current angina were in NYHA functional class 
III or IV versus 58% of patients with no angina(3, 5). I have extended these 
observations to include a description of the KCCQ clinical summary score and 
symptoms and signs according to baseline angina status. The KCCQ clinical summary 
score showed a gradient of worsening baseline health-related quality of life with 
increasing severity of angina. In PARADIGM-HF, patients with severe angina were 
also considerably more likely to report rest and nocturnal dyspnoea and fatigue 
compared to those without angina. Similarly, patients with severe angina were twice as 
likely to have peripheral oedema and an elevated jugular venous pressure. Notably, 
despite this greater functional limitation, and worse symptoms and signs, patients with 
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more severe angina had a higher average LVEF and higher systolic BP when 
compared to patients with no angina, consistent with the findings in CORONA and 
CHARM(3, 5). There was also little gradient in NT pro BNP or estimated glomerular 
filtration rate according to severity of angina. Therefore, it now seems clear that there 
is a disconnection between symptoms, signs and functional limitation due to heart 
failure and measures of haemodynamic and physiological severity in patients with 
angina. This finding seems to indicate that myocardial ischaemia, rather than worse 
physiological status, may exacerbate functional status and heart failure symptoms in 
some patients with HF-REF. 
One unexpected finding was that patients with severe angina were least likely to have 
undergone prior PCI. The results of coronary angiography were not available but 
patients with severe angina may have had more complex coronary anatomy that was 
less amenable to revascularization. It is also possible the so-called ‘risk treatment 
paradox’ contributed to the underutilization of PCI in this group i.e. patients with more 
severe heart failure symptoms and functional limitation may have been less likely to 
be considered for revascularization(131-135).  However, a similar gradient in prior 
coronary artery bypass grafting was not observed, making this explanation less likely.  
Patients with moderate and severe angina were also less likely to have an ICD or CRT 
device implanted when compared to patients with no angina.  The higher proportion of 
patients with NYHA class IV symptoms may (at least partially) account for why fewer 
patients received ICDs.   
The relationship between severity of angina symptoms and clinical outcomes 
In CORONA and CHARM current angina was associated with a higher risk of acute 
coronary syndrome but the risk of all-cause and CV death was similar to that of 
patients with no history of angina(3, 5).  There was also a lack of association between 
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angina and all-cause death in retrospective analyses of COMET and a large single-
centre US study (n=2376)(85, 99). The STICH trial has reported the relationship 
between severity of angina and all-cause death. Patients with moderate or severe 
angina (defined as a CCS ≥ 2) were at higher risk of all-cause death when compared 
with patients with no angina (adjusted HR 1.27, 1.04-1.57; p=0.02).  As only 58 
patients in STICH had moderate or severe angina this association required 
corroboration(127).   
Our study builds upon the aforementioned analyses by examining the relationship 
between severity of angina and a range of non-fatal and fatal outcomes in a large 
population with HF. As in the prior studies, patients in PARADIGM-HF with angina 
were at higher risk of coronary events but this risk was proportional to the severity of 
angina. Patients with severe angina had a higher risk of unstable angina and non-fatal 
MI (the former risk was almost 6-fold higher) when compared to patients with no 
angina but there was no association between mild angina symptoms and any coronary 
outcome. However, patients in PARADIGM-HF with angina were also at higher risk 
of all-cause and CV death compared to patients with no angina – but again this 
heightened risk was only observed in patients with severe angina symptoms.  This 
difference is probably explained by the earlier studies (except for STICH whose 
findings were similar to our own) combining all patients with angina when 
PARADIGM-HF clearly shows that the risk of death is only increased among those 
with the most severe symptoms and not in those with less severe angina(127). 
Notably, the increase in CV death was mainly accounted for by an increase in risk of 
sudden death, rather than in risk of death due to worsening heart failure.  
Interestingly, in PARADIGM-HF severe angina was not an independent predictor of 
heart failure hospitalization in our multivariable analysis, although the p-value for this 
comparison was of borderline statistical significance (p=0.07).  While the strict 
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interpretation of our analysis showing no association is consistent with the findings 
from CHARM and COMET, current angina in CORONA was associated with a higher 
risk of HF hospitalization (adjusted HR 1.35, 1.13-1.63; p=0.001)(3, 5).  It remains 
possible, therefore, that angina may be associated with HF hospitalization. 
The potentially important implication of our findings is that while relief of myocardial 
ischaemia in patients with severe angina might improve functional status and prevent 
adverse outcomes, such benefits might be harder to show in patients with less severe 
angina. As patients with severe angina have an indication for revascularization, they 
have been excluded from previous and ongoing trials (e.g. the STICH trial) comparing 
CABG and medical therapy in patients with CAD and severe left ventricular 
dysfunction. In the STICH trial mortality rates in those assigned to medical therapy 
alone were similar whether angina was present or absent at baseline. Patients with and 
without angina had a similar benefit from CABG in both the original STICH trial and 
the 10 year extension study.  No conclusions can be drawn from STICH with regard to 
severity of symptoms as CCS ≥3 was an exclusion criterion(77, 78, 81, 127).   
In the on-going Study of Efficacy and Safety of Percutaneous Coronary Intervention to 
Improve Survival in Heart Failure (REVIVED-BCIS2) trial, designed to investigate 
the role of PCI in patients with HF, those with significant angina (defined as ≥ CCS 
class 3 symptoms) are excluded(78).  It is notable, however, that while patients with 
severe angina have been excluded from these trials on the basis of having an existing 
guideline recommendation for revascularization, the low rate of prior revascularization 
observed in PARADIGM-HF and earlier studies suggests that clinical practice does 
not follow the guidelines in this instance.  
Limitations 
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Our study has a number of limitations.  The sub-groups in our analysis were not pre-
specified and our study therefore has the same limitations associated as all post-hoc 
analyses. The presence and severity of angina used to stratify patients into groups was 
determined by investigator-reported history. Finally, I did not have the results of 
coronary angiography and the severity of CAD may be independently related to 
prognosis(113).  It is unclear how our findings would be affected by these results. 
Conclusion 
In summary, patients with HF-REF, CAD and severe angina experience more 
functional limitation and are at higher risk of MI, all-cause and CV death. These 
findings raise the possibility that coronary revascularization and anti-ischaemic 
pharmacotherapy might improve outcomes in this population but these strategies need 
to be tested in prospective trials. 
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Table 17. PARADIGM-HF: baseline characteristics of patients with HF-REF stratified 
by severity of angina at baseline. 
 
Angina severity 
 
Variable 
 
No angina 
(n=3869) 
 
 
Mild 
(n=447) 
 
Moderate 
(n=884) 
 
Severe 
(n=394) 
 
 
 
p value 
Age 65.0 ± 10.7 66.9 ± 9.6 66.1 ± 9.5 67.1 ± 9.2 <0.01 
Female 711 (18.4) 92 (20.6) 214 (24.2) 87 (22.1) <0.01 
Race      
Caucasian 2501 (64.6%) 361 (80.8%) 759 (85.9%) 359 (91.1%) <0.01 
Black 134 (3.5%) 13 (2.9%) 13 (1.5%) 2 (0.5%) <0.01 
Asian 822 (21.3%) 45 (10.1%) 74 (8.4%) 22 (5.6%) <0.01 
Other 412 (10.7%) 28 (6.3%) 38 (4.3%) 11 (2.8%) <0.01 
Current smoker 563 (14.6) 67 (15.0) 133 (15.0) 15.7 (14.5) 0.98 
LVEF (%) 29.4 ± 6.3 29.8 ±6.0 31.4 ± 5.7 31.7 ± 5.1 <0.01 
Systolic BP mm/Hg 121.0 ± 15.4 122.0 ±15.4 124.9 ±14.3 125.4 ±13.4 <0.01 
Heart Rate bpm 71.8 ± 12.0 70.6 ± 10.3 72.2 ± 11.6 72.0 ± 11.9  0.12 
BMI kg/m2 28.0 ± 5.4 28.9 ± 5.4 28.8 ± 5.1 28.8 ± 5.1 <0.01 
Medical History      
MI 2406 (62.2%) 325 (72.7%) 588 (66.5%) 315 (79.9%) <0.01 
PCI 1251 (32.3%) 191 (42.7%) 267 (30.2%) 92 (23.4%) <0.01 
CABG 852 (22.0) 143 (32.0) 211 (23.9) 97 (24.6) <0.01 
Hypertension 2765 (71.5%) 341 (76.3%) 768 (86.9%) 361 (91.6%) <0.01 
Diabetes Mellitus 1513 (39.1%) 185 (41.4%) 337 (38.1%) 146 (37.1%) 0.57 
AF  1283 (33.2%) 176 (39.4%) 373 (42.2%) 164 (41.6%) <0.01 
Stroke 385 (10.0%) 46 (10.3%) 97 (11.0%) 39 (9.9%)  0.84 
Pacemaker 538 (13.9%) 87 (19.5%) 82 (9.3%) 36 (9.1%) <0.01 
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CRT 282 (7.3) 40 (9.0) 34 (3.9) 22 (5.6) <0.01 
ICD  694 (17.9%) 115 (25.7%) 90 (10.2%) 31 (7.9%) <0.01 
Symptoms      
NYHA class III/IV  849 (22.0%) 84 (18.8%) 337 (38.3%) 266 (67.7%) <0.01 
Rest dyspnoea 125 (3.2%) 22 (4.9%) 48 (5.5%) 39 (9.9%) <0.01 
PND 171 (4.4%) 16 (3.6%) 55 (6.2%) 43 (10.9%) <0.01 
Orthopnea 263 (6.8%) 34 (7.6%) 67 (7.6%) 27 (6.9%) 0.80 
Fatigue 1842 (47.7%) 258 (58.0%) 610 (69.2%) 312 (79.4%) <0.01 
KCCQ score 69.5 ± 29.1 68.8 ± 27.2 66.8 ± 23.0 60.9 ± 23.3 <0.01 
Signs      
Raised JVP 335 (8.7%) 31 (7.0%) 90 (10.2%) 42 (10.7%) 0.13 
Oedema  723 (18.7%) 114 (25.6%) 258 (29.3%) 149 (37.9%) <0.01 
Pulmonary rales  277 (7.2%) 29 (6.5%) 122 (13.8%) 55 (14.0%) <0.01 
Third heart sound 350 (9.1%) 34 (7.6%) 104 (11.8%) 35 (8.9%) 0.04 
Lab measurements      
Estimated GFR 66.1 ± 19.4 63.6 ± 19.2 67.0 ± 18.2 64.5 ± 20.9 <0.01 
Median NT-proBNP* 1593 (890-3103) 1395 (770-2762) 1411 (766-2612) 1767 (898-3431) <0.01 
Medication      
LCZ696 randomisation 1926 (49.8%) 228 (51.0%) 426 (48.2%) 198 (50.3%) 0.76 
Loop or thiazide 3018 (78.0%) 358 (80.1%) 704 (79.6%) 318 (80.7%) 0.39 
Beta-blocker 3594 (92.9%) 432 (96.6%) 818 (92.5%) 366 (92.9%) 0.02 
MRA 1988 (51.4%) 195 (43.6%) 493 (55.8%) 269 (68.3%) <0.01 
Digoxin 1029 (26.6%) 92 (20.6%) 208 (23.5%) 87 (22.1%) <0.01 
Antiplatelet 2577 (66.6%) 336 (75.2%) 575 (65.1%) 275 (69.8%) <0.01 
Anticoagulant 1136 (29.4%) 145 (32.4%) 298 (33.7%) 111 (28.2%) 0.04 
 Statins 2639 (68.2) 360 (80.5) 602 (68.1) 265 (67.3) <0.01 
* LVEF – left ventricular ejection fraction; BP – blood pressure; bpm – beats per minute; BMI 
– body mass index; MI – myocardial infarction; PCI – percutaneous coronary intervention; 
CABG – coronary artery bypass graft surgery; AF – atrial fibrillation; ICD – implantable 
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cardioverter defibrillator; CRT – cardiac resynchronization therapy; NYHA – New York Heart 
Association; PND – paroxysmal nocturnal dyspnea; KCCQ - Kansas City Cardiomyopathy 
Questionnaire; JVP –jugular venous pressure; GFR – glomerular filtration rate; NT-proBNP - 
N-terminal proBNP.   
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Table 18. PARADIGM-HF: event rates according to severity of chest pain at baseline.  
Severity of chest pain 
 
No 
angina 
Mild 
angina 
Moderate 
angina 
Severe 
angina 
 (n=3869) (n=447) (n=884) (n=394) 
CV death or HF 
hospitalization 
954 
(24.7) 
105 
(23.5) 
217 
(24.6) 
137 
(34.8) 
CV death 
 
577 
(14.9) 
63 
(14.1) 
129 
(14.6) 
95 
(24.1) 
HF hospitalization 561 
(14.5) 
65 
(14.5) 
121 
(13.7) 
71 
(18.0) 
Non-fatal MI 
114 
(2.9) 
21 
(4.7) 
32 
(3.6) 
19 
(4.8) 
Fatal or non-fatal MI 
123  
(3.2) 
23 
(5.1) 
36 
(4.1) 
22 
(5.6) 
UA hospitalization 
39  
(1.0) 
7  
(1.6) 
9  
(2.2) 
22  
(5.6) 
UA or non-fatal MI 
148 
(3.8) 
25 
(5.6) 
47 
(5.3) 
37 
(9.4) 
All-cause death 
 
717 
(18.5) 
82 
(18.3) 
166 
(18.8) 
107 
(27.2) 
Sudden death 
270  
(7.0) 
21 
(4.7) 
57  
(6.4) 
50 
(12.7) 
Death due to HF 
144  
(3.7) 
14  
(3.1) 
2.1  
(2.4) 
19  
(4.8) 
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Table 19. PARADIGM-HF unadjusted analysis: the relationship between severity of 
chest pain and clinical outcomes. 
 
 
Mild vs. 
No angina 
Moderate vs. 
No angina 
Severe vs. 
No angina 
 
 
HR 
(95% CI) 
 
P value 
HR 
(95% CI) 
 
P value 
HR 
(95% CI) 
 
P value 
CV death/ 
HFH 
0.89 
(0.72-1.08) 
0.24 0.99 
(0.85-1.14) 
0.87 1.56 
(1.31-1.87) 
<0.01 
CV death 
 
0.88 
(0.68-1.14) 
0.33 0.97 
(0.80-1.17) 
0.74 1.77 
(1.43-2.20) 
<0.01 
HFH 0.94 
(0.72-1.21) 
0.62 0.94 
(0.77-1.14) 
0.52 1.37 
(1.07-1.75) 
0.01 
Non-fatal 
MI 
1.51 
(0.95-2.41) 
0.08 1.23 
(0.83-1.81) 
0.31 1.78 
(1.09-2.89) 
0.02 
Fatal or 
non-fatal 
MI 
1.53 
(0.98-2.39) 
0.06 1.28 
(0.88-1.85) 
0.20 1.92 
(1.22-3.02) 
0.01 
UA 
1.46  
(0.65-3.27) 
0.35 2.13  
(1.23-3.68) 
<0.01 6.17  
(3.65-10.40) 
<0.01 
UA or non-
fatal MI 
1.39 
(0.91-2.12) 
0.13 1.40 
(1.01-1.94) 
0.05 2.75 
(1.92-3.94) 
<0.01 
All-cause 
death 
 
0.91 
(0.73-1.15) 
0.45 1.00 
(0.85-1.19) 
0.98 1.62 
(1.32-1.98) 
<0.01 
Sudden 
death 
0.63 
(0.41-0.98) 
0.04 0.92  
(0.69-1.22) 
0.56 1.97  
(1.45-2.66) 
<0.01 
Death due 
to HF 
0.78  
(0.45-1.34) 
0.37 0.63  
(0.40-1.00) 
0.05 1.43  
(0.89-2.31) 
0.14 
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Table 20 PARADIGM-HF adjusted analysis: the relationship between severity of chest 
pain and clinical outcomes. 
 
 
Mild vs. 
No angina 
Moderate vs. 
No angina 
Severe vs. 
No angina 
 
 
HR 
(95% CI) 
 
P value 
HR 
(95% CI) 
 
P value 
HR 
(95% CI) 
 
P value 
CV death/ 
HFH 
0.89 
(0.73-1.09) 
0.27 1.06  
(0.92-1.24) 
0.42 1.41  
(1.17-1.70) 
<0.01 
CV death 
 
0.93  
(0.72-1.22) 
0.61 1.07  
(0.88-1.31) 
0.47 1.60  
(1.27-2.01) 
<0.01 
HFH 0.91  
(0.69-1.17) 
0.43 1.02  
(0.83-1.25) 
0.84 1.27  
(0.98-1.64) 
0.07 
Non-fatal 
MI 
1.45  
(0.91-2.32) 
0.12 1.27  
(0.86-1.90) 
0.23 1.84  
(1.11-3.07) 
0.02 
Fatal or 
non-fatal 
MI 
1.45 
(0.93-2.28) 
0.10 1.30 
(0.89-1.90) 
0.17 1.90 
(1.18-3.06) 
0.01 
UA 
1.37 
(0.61-3.07) 
0.45 2.02  
(1.15-3.53) 
0.01 5.81  
(3.28-10.28) 
<0.01 
UA or 
non-fatal 
MI 
1.29 
(0.84-1.98) 
0.24 1.40 
(1.01-1.96) 
0.05 2.64 
(1.80-3.88) 
<0.01 
All-cause 
death 
 
0.95 
(0.75-1.19) 
0.64 1.10 
(0.93-1.31) 
0.28 1.48 
(1.20-1.84) 
<0.01 
Sudden 
death 
0.73 
(0.46-1.14) 
0.16 1.01  
(0.76-1.36) 
0.93 1.86  
(1.35-2.57) 
<0.01 
Death due 
to HF 
0.77  
(0.44-1.33) 
0.35 0.78  
(0.49-1.25) 
0.30 1.32  
(0.80-2.17) 
0.28 
 
** Adjusted for age, ejection fraction, NYHA class, serum creatinine, diabetes mellitus, 
COPD, beta blocker use, systolic blood pressure, BMI, time from first diagnosis of HF, 
smoking status, gender, (log) NT-proBNP levels and randomization to LZC696.  
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Figure 8: Kaplan-Meier curves of the relationship between severity of angina and 
clinical outcomes. 
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Figure legend 
Figure 8:Kaplan-Meier curves of the relationship between severity of angina, all-
cause death, HF outcomes  
and coronary outcomes. i) Cardiovascular death or HF hospitalization ii) CV death iii) 
HF hospitalization iv) All-cause death v) Sudden death vi) Death due to HF. 
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Final Discussion 
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My thesis examined the clinical characteristics and prognostic importance of 
angina in patients with HF.  Very few studies had examined the association 
between these two conditions and a number of themes emerged from our 
analyses.   
In patients with HF-REF and HF-PEF, current angina was associated with more 
functional limitation than in patients with no angina.  Worse functional status 
likely reflected myocardial ischaemia rather than severity of HF.  In CORONA, 
this was evidenced by patients with angina and HF-REF having more NYHA 
class III or IV symptoms, despite having higher mean LVEF and lower NT-
proBNP levels. This suggests their HF was actually less severe than patients 
with no angina(3).  In CHARM I was able to replicate the findings of 
CORONA whilst also identifying a similar association in patients with heart 
failure and preserved ejection fraction(5).  PARADIGM-HF examined the 
importance of severity of angina in patients with HF-REF.  The relationship 
between functional limitation and angina became stronger with worsening 
severity of angina symptoms.    
In patients with HF-REF from CORONA and CHARM, current angina was 
associated with a higher risk of ACS than in patients with no angina.  A similar 
relationship was identified in patients with HF-PEF in CHARM.  Patients with 
past angina in both studies also had a higher risk of ACS but the relationship 
was not as strong as in patients with current angina(3, 5).  In PARADIGM-HF, 
patients with severe angina were at significantly higher risk of non-fatal MI and 
angina when compared to patients with angina.  Patients with moderate angina 
were only at higher risk of UA (but not MI) and there was no association 
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between mild angina symptoms and either UA or MI.  The results of the 
PARADIGM analysis suggest severity of angina rather than simply the 
presence of angina per se may be a stronger predictor of adverse outcomes.    
The importance of angina on HF outcomes is less clear.  In CORONA, patients 
with current angina were at higher risk of HF hospitalization compared to 
patients with no angina.  This suggested chronic myocardial ischaemia (i.e. 
angina) might be responsible for worsening HF symptoms in some patients(3).  
However, no association between angina and HF outcomes was evident in 
CHARM.  As discussed previously, this may reflect differences in the two trial 
populations or that I was only able to adjust for prior HF hospitalization in 
CHARM but not in CORONA(3, 5).  The findings from PARADIGM-HF also 
highlight a third possibility.  In PARADIGM-HF there was a borderline 
significant increase in HF hospitalization in patients with severe angina (but not 
mild or moderate angina) compared to patients with no angina.  Neither 
CHARM nor CORONA collected data on severity of angina symptoms and it is 
possible the differences in severity of angina between the two studies accounted 
for this difference.    
Patients with current angina in CORONA and CHARM and patients with mild 
or moderate angina in PARADIGM-HF were not at higher risk of CV or all-
cause mortality.  Only patients with severe angina in PARADIGM-HF were 
more at higher risk of CV or all-cause mortality.   
One major limitation of all the analyses performed in my thesis is that they use 
data from randomised controlled trials.  Selection bias is inevitable and the 
patient population may not be fully representative of a ‘real world’ population.  
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This is particularly true of CORONA, which was limited to patients over the 
age of 60.  Another limitation of our studies was that we were unable to 
correlate symptoms with coronary angiography or objective tests looking for 
evidence of myocardial ischaemia.  The latter would also have allowed us to 
examine the potential importance of asymptomatic myocardial ischaemia.     
Nevertheless, a common theme that emerges is that symptomatic myocardial 
ischaemia or angina (particularly if it is severe) is a potentially important 
therapeutic target. STICH and the on-going REVIVED-BCIS2 trial excluded 
patients with severe angina (defined as ≥ CCS class 3), the group who could 
stand to benefit the most(77, 78, 81).  As detailed previously, while patients 
with severe angina have been excluded from these trials on the basis of having 
an existing guideline recommendation for revascularization, the low rate of 
prior revascularization observed in PARADIGM-HF and earlier studies 
suggests that clinical practice does not follow this guideline recommendation.  
Whether this is indicative of the underlying coronary anatomy in patients with 
severe angina is not known and requires further research.  Most importantly, 
prospective studies are needed to establish whether patients with angina stand 
to benefit from a targeted treatment strategy.  Randomized controlled trials of 
medical anti-anginal therapy and coronary revascularisation (in patients with 
suitable anatomy) in patients with angina and HF might improve functional 
status and clinical outcomes.  
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Appendix 1: Assessment of bias in prior studies examining prognostic 
importance of angina in patients with Heart Failure 
 Study  
Domain Mentz (2012) Mentz (2014) 
Representativeness  
(expressed cohort) 
No No 
Selection  
(non-exposed cohort) 
No No 
Ascertainment of 
exposures 
Yes Yes 
Demonstration outcome 
of interest not present at 
start of study 
Yes Yes 
Comparability of 
cohorts on basis of 
design or analysis  
Yes Yes 
Assessment of outcome Yes Yes 
Follow-up sufficient for 
outcomes to occur 
Yes Yes 
Adequacy of follow-up  Not stated Not stated 
 
 
